Metabolite,Reference,ID,DOI,tCr_u,tCr_std,IU_u,IU_std,mM_u,mM_std,Group,Tissue,Title,GM,GM_Std,WM,WM_Std,N_Total,Female,Male,Age,Age_Std
Asc,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,1.41,0.165,1.41,0.165,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
Asp,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,1.86,0.289,1.86,0.289,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
Asp,2017_suri_152,1,10.1016/j.neuroimage.2017.03.031,0.364,0.022,0.0,0.0,0.0,0.0,Control,GM,Effect of age and the APOE gene on metabolite concentrations in the posterior cingulate cortex.,0.6,0.03,0.23,0.03,30.0,13.0,17.0,23.87,4.95
Asp,2019_reid_45,1,10.1093/schbul/sbx190,0.0,0.0,1.49,0.21,0.0,0.0,Control,GM,7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.,0.7140000000000001,0.078,0.254,0.077,21.0,5.0,16.0,23.5,4.5
Asp,2019_wiegers_62,1,10.1007/s00125-019-4862-9,0.0,0.0,2.07,0.34,2.07,0.34,Control,WM,Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status.,0.265,0.042,0.713,0.047,13.0,7.0,6.0,25.5,5.5
Asp,2021_bednarik_15,1,10.3389/fnins.2021.609485,0.0,0.0,3.7,0.3,3.7,0.3,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7240000000000001,0.0178,0.18600000000000003,0.031,12.0,0.0,12.0,26.0,5
Asp,2021_bednarik_15,2,10.3389/fnins.2021.609485,0.0,0.0,3.68,0.3,3.68,0.3,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7340000000000001,0.018000000000000002,0.17800000000000002,0.032,12.0,0.0,12.0,26.0,5
Cr,2018_caravaggio_28,1,10.1016/j.euroneuro.2017.12.002,0.0,0.0,7.04,1.07,0.0,0.0,Healthy,WM,Reduced insulin sensitivity may be related to less striatal glutamate: An (1)H-MRS study in healthy non-obese humans.,0.2921,0.0391,0.6297999999999999,0.0621,17.0,9.0,8.0,28.35,9.53
Cr,2018_caravaggio_28,2,10.1016/j.euroneuro.2017.12.002,0.0,0.0,6.56,1.35,0.0,0.0,Healthy,WM,Reduced insulin sensitivity may be related to less striatal glutamate: An (1)H-MRS study in healthy non-obese humans.,0.2465,0.028399999999999998,0.6658,0.06709999999999999,17.0,9.0,8.0,28.35,9.53
Cr,2018_chiu_193,4,10.1016/j.schres.2017.07.021,0.0,0.0,14.71,1.75,14.71,1.75,Control,GM,In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study.,0.6076,0.0858,0.2432,0.0821,14.0,5.0,9.0,27.71,5.88
Cr,2018_egerton_23,7,10.1038/s41380-018-0082-9,0.0,0.0,6.4,0.48,6.4,0.48,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
Cr,2018_egerton_23,8,10.1038/s41380-018-0082-9,0.0,0.0,5.06,0.37,5.06,0.37,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
Cr,2018_egerton_23,9,10.1038/s41380-018-0082-9,0.0,0.0,5.23,0.3,5.23,0.3,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
Cr,2018_egerton_23,10,10.1038/s41380-018-0082-9,0.0,0.0,7.11,0.42,7.11,0.42,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
Cr,2018_egerton_23,11,10.1038/s41380-018-0082-9,0.0,0.0,5.4,0.6,5.4,0.6,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
Cr,2018_egerton_23,12,10.1038/s41380-018-0082-9,0.0,0.0,4.83,0.13,4.83,0.13,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
Cr,2018_egerton_23,1,10.1038/s41380-018-0082-9,0.0,0.0,6.48,0.45,6.48,0.45,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
Cr,2018_egerton_23,2,10.1038/s41380-018-0082-9,0.0,0.0,5.07,0.37,5.07,0.37,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
Cr,2018_egerton_23,3,10.1038/s41380-018-0082-9,0.0,0.0,5.22,0.25,5.22,0.25,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
Cr,2018_egerton_23,4,10.1038/s41380-018-0082-9,0.0,0.0,7.17,0.57,7.17,0.57,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
Cr,2018_egerton_23,5,10.1038/s41380-018-0082-9,0.0,0.0,5.34,0.3,5.34,0.3,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
Cr,2018_egerton_23,6,10.1038/s41380-018-0082-9,0.0,0.0,4.91,0.22,4.91,0.22,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
Cr,2018_huber_225,3,10.1016/j.jad.2017.07.052,0.0,0.0,6.49,0.6,0.0,0.0,Control,GM,Relationship of executive functioning deficits to N-acetyl aspartate (NAA) and gamma-aminobutyric acid (GABA) in youth with bipolar disorder.,0.7020000000000001,0.031,0.0,0.0,10.0,5.0,5.0,19.0,1.56
Cr,2018_huber_225,4,10.1016/j.jad.2017.07.052,0.0,0.0,6.81,0.46,0.0,0.0,Control,GM,Relationship of executive functioning deficits to N-acetyl aspartate (NAA) and gamma-aminobutyric acid (GABA) in youth with bipolar disorder.,0.642,0.047,0.0,0.0,10.0,5.0,5.0,19.0,1.56
Cr,2019_bossong_76,1,10.1001/jamapsychiatry.2018.3252,0.0,0.0,7.42,1.1,7.42,1.1,Control,GM,Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis.,0.64,0.07,0.33,0.08,30.0,16.0,14.0,24.7,3.8
Cr,2019_davitz_50,9,10.1002/jmri.26718,0.0,0.0,5.9,1.5,5.9,1.5,Control,WM,Quantitative multivoxel proton MR spectroscopy for the identification of white matter abnormalities in mild traumatic brain injury: Comparison between regional and global analysis.,0.0,0.0,0.0,0.0,12.0,4.0,8.0,34.0,0
Cr,2019_davitz_50,10,10.1002/jmri.26718,0.0,0.0,4.8,1.0,4.8,1.0,Control,WM,Quantitative multivoxel proton MR spectroscopy for the identification of white matter abnormalities in mild traumatic brain injury: Comparison between regional and global analysis.,0.0,0.0,0.0,0.0,12.0,4.0,8.0,34.0,0
Cr,2019_pflugrad_14,12,10.1371/journal.pone.0221626,0.0,0.0,3.23,0.0,0.0,0.0,Control,WM,Cerebral metabolite alterations in patients with posttransplant encephalopathy after liver transplantation,0.0,0.0,0.0,0.0,20.0,14.0,6.0,47.8,10.8
Cr,2019_reid_45,1,10.1093/schbul/sbx190,0.0,0.0,2.39,0.22,0.0,0.0,Control,GM,7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.,0.7140000000000001,0.078,0.254,0.077,21.0,5.0,16.0,23.5,4.5
Cr,2020_blest-hopley_25,2,10.1111/adb.12827,0.0,0.0,7.665,0.784,0.0,0.0,Control,GM,Adolescent-onset heavy cannabis use associated with significantly reduced glial but not neuronal markers and glutamate levels in the hippocampus.,0.6365,0.058,0.3099,0.098,21.0,12.0,9.0,24.24,4.11
Cr,2020_kumar_25,1,10.1038/s41380-018-0104-7,0.0,0.0,2.98,0.69,2.98,0.69,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.743,0.067,0.111,0.064,45.0,16.0,29.0,27.89,7.54
Cr,2020_kumar_25,2,10.1038/s41380-018-0104-7,0.0,0.0,2.6,0.39,2.6,0.39,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.637,0.046,0.285,0.051,45.0,16.0,29.0,27.89,7.54
Cr,2020_kumar_25,3,10.1038/s41380-018-0104-7,0.0,0.0,3.28,0.57,3.28,0.57,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.6759999999999999,0.051,0.226,0.085,45.0,16.0,29.0,27.89,7.54
Cr,2021_gajdosik_34,1,10.1002/nbm.4538,0.0,0.0,5.7,0.4,5.7,0.4,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,2.0,1.0,32.5,10.2
Cr,2021_gajdosik_34,2,10.1002/nbm.4538,0.0,0.0,5.9,0.3,5.9,0.3,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,1.0,2.0,32.5,10.2
Cr,2021_steinegger_26,1,10.1111/adb.13027,0.0,0.0,11.0,0.82,11.0,0.82,Control,GM,Neurometabolic alterations in the nucleus accumbens of smokers assessed with H-1 magnetic resonance spectroscopy: The role of glutamate and neuroinflammation,0.8075,0.058899999999999994,0.1925,0.058899999999999994,25.0,0.0,20.0,26.3,4.27
GABA,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,0.78,0.247,0.78,0.247,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
GABA,2018_huber_225,3,10.1016/j.jad.2017.07.052,0.0,0.0,1.14,0.29,0.0,0.0,Control,GM,Relationship of executive functioning deficits to N-acetyl aspartate (NAA) and gamma-aminobutyric acid (GABA) in youth with bipolar disorder.,0.7020000000000001,0.031,0.0,0.0,10.0,5.0,5.0,19.0,1.56
GABA,2018_huber_225,4,10.1016/j.jad.2017.07.052,0.0,0.0,1.2,0.29,0.0,0.0,Control,GM,Relationship of executive functioning deficits to N-acetyl aspartate (NAA) and gamma-aminobutyric acid (GABA) in youth with bipolar disorder.,0.642,0.047,0.0,0.0,10.0,5.0,5.0,19.0,1.56
GABA,2018_marenco_43,1,10.1038/s41386-018-0134-5,0.096,0.009,0.001,0.0,0.0,0.0,Healthy,GM,Role of gamma-amino-butyric acid in the dorsal anterior cingulate in age-associated changes in cognition,0.6964,0.052199999999999996,0.0,0.0,229.0,127.0,102.0,29.98,9.16
GABA,2018_marenco_43,2,10.1038/s41386-018-0134-5,0.106,0.011,0.001,0.0,0.0,0.0,Healthy,WM,Role of gamma-amino-butyric acid in the dorsal anterior cingulate in age-associated changes in cognition,0.19870000000000002,0.0521,0.0,0.0,113.0,51.0,62.0,32.17,9.46
GABA,2018_prescot_43,1,10.1038/npp.2017.156,0.0,0.0,0.988,0.094,0.988,0.094,Healthy,GM,In Vivo Detection of CPP-115 Target Engagement in Human Brain.,0.62,0.05,0.38,0.05,6.0,0.0,6.0,34.2,16.8
GABA,2018_prescot_43,3,10.1038/npp.2017.156,0.0,0.0,0.81,0.023,0.81,0.023,Healthy,GM,In Vivo Detection of CPP-115 Target Engagement in Human Brain.,0.62,0.05,0.38,0.05,6.0,0.0,6.0,34.2,16.8
GABA,2018_prescot_43,5,10.1038/npp.2017.156,0.0,0.0,0.922,0.027,0.922,0.027,Healthy,GM,In Vivo Detection of CPP-115 Target Engagement in Human Brain.,0.62,0.05,0.38,0.05,6.0,0.0,6.0,34.2,16.8
GABA,2018_prescot_43,7,10.1038/npp.2017.156,0.0,0.0,0.932,0.01,0.932,0.01,Healthy,GM,In Vivo Detection of CPP-115 Target Engagement in Human Brain.,0.62,0.05,0.38,0.05,6.0,0.0,6.0,34.2,16.8
GABA,2018_prescot_43,9,10.1038/npp.2017.156,0.0,0.0,0.839,0.05,0.839,0.05,Healthy,GM,In Vivo Detection of CPP-115 Target Engagement in Human Brain.,0.61,0.06,0.39,0.06,6.0,0.0,6.0,34.2,16.8
GABA,2018_prescot_43,11,10.1038/npp.2017.156,0.0,0.0,1.475,0.092,1.475,0.092,Healthy,GM,In Vivo Detection of CPP-115 Target Engagement in Human Brain.,0.61,0.06,0.39,0.06,6.0,0.0,6.0,34.2,16.8
GABA,2018_prescot_43,13,10.1038/npp.2017.156,0.0,0.0,1.381,0.223,1.381,0.223,Healthy,GM,In Vivo Detection of CPP-115 Target Engagement in Human Brain.,0.61,0.06,0.39,0.06,6.0,0.0,6.0,34.2,16.8
GABA,2018_prescot_43,15,10.1038/npp.2017.156,0.0,0.0,0.94,0.015,0.94,0.015,Healthy,GM,In Vivo Detection of CPP-115 Target Engagement in Human Brain.,0.61,0.06,0.39,0.06,6.0,0.0,6.0,34.2,16.8
GABA,2018_sheth_276,3,10.1016/j.pscychresns.2018.04.004,0.0,0.0,0.37,0.03,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.7021999999999999,0.03,0.2978,0.03,24.0,5.0,19.0,36.2,9.7
GABA,2018_sheth_276,4,10.1016/j.pscychresns.2018.04.004,0.0,0.0,0.34,0.01,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.6139,0.043,0.3861,0.043,24.0,5.0,19.0,36.2,9.7
GABA,2018_tiwari_80,1,10.1002/mrm.27142,0.0,0.0,0.8,0.06,0.8,0.06,Healthy,GM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.61,0.03,0.23,0.02,6.0,3.0,3.0,27.0,5
GABA,2018_tiwari_80,2,10.1002/mrm.27142,0.0,0.0,0.51,0.07,0.51,0.07,Healthy,WM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.16,0.05,0.81,0.08,6.0,3.0,3.0,27.0,5
GABA,2018_tiwari_80,3,10.1002/mrm.27142,0.0,0.0,0.87,0.06,0.87,0.06,Healthy,WM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.0,0.0,0.0,0.0,6.0,3.0,3.0,27.0,5
GABA,2018_tiwari_80,5,10.1002/mrm.27142,0.0,0.0,1.08,0.08,1.08,0.08,Healthy,GM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.0,0.0,0.0,0.0,6.0,3.0,3.0,27.0,5
GABA,2018_tiwari_80,6,10.1002/mrm.27142,0.0,0.0,0.46,0.03,0.46,0.03,Healthy,GM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.0,0.0,0.0,0.0,6.0,3.0,3.0,27.0,5
GABA,2019_chan_14,1,10.1371/journal.pone.0208666,0.0,0.0,3.308,0.325,0.0,0.0,Control,GM,Relating excitatory and inhibitory neurochemicals to visual perception: A magnetic resonance study of occipital cortex between migraine events,0.643,0.037,0.23,0.034,16.0,8.0,8.0,27.125,4.63
GABA,2019_duncan_50,1,10.1002/jmri.26706,0.0,0.0,5.5,0.4,0.0,0.0,Healthy,GM,Investigating GABA concentrations measured with macromolecule suppressed and unsuppressed MEGA-PRESS MR spectroscopy and their relationship with BOLD responses in the occipital cortex.,0.65,0.03,0.25,0.03,31.0,5.0,26.0,23.0,3.1
GABA,2019_duncan_50,3,10.1002/jmri.26706,0.0,0.0,2.9,0.6,0.0,0.0,Healthy,GM,Investigating GABA concentrations measured with macromolecule suppressed and unsuppressed MEGA-PRESS MR spectroscopy and their relationship with BOLD responses in the occipital cortex.,0.65,0.03,0.25,0.03,31.0,5.0,26.0,23.0,3.1
GABA,2019_ferland_237,1,10.1007/s00221-019-05691-z,0.049,0.016,0.834,0.239,0.834,0.239,Healthy,WM,Longitudinal assessment of (1)H-MRS (GABA and Glx) and TMS measures of cortical inhibition and facilitation in the sensorimotor cortex.,0.22399999999999998,0.04,0.743,0.048,10.0,5.0,5.0,26.0,4
GABA,2019_ferland_237,2,10.1007/s00221-019-05691-z,0.05,0.015,0.888,0.254,0.888,0.254,Healthy,WM,Longitudinal assessment of (1)H-MRS (GABA and Glx) and TMS measures of cortical inhibition and facilitation in the sensorimotor cortex.,0.22399999999999998,0.052000000000000005,0.742,0.057999999999999996,10.0,5.0,5.0,26.0,4
GABA,2019_hong_14,1,10.1371/journal.pone.0223702,0.13,0.06,0.0,0.0,0.0,0.0,Healthy,WM,A comparison of sLASER and MEGA-sLASER using simultaneous interleaved acquisition for measuring GABA in the human brain at 7T.,0.275,0.0575,0.685,0.061900000000000004,12.0,3.0,9.0,29.33,4.49
GABA,2019_hong_14,4,10.1371/journal.pone.0223702,0.28,0.03,0.0,0.0,0.0,0.0,Healthy,GM,A comparison of sLASER and MEGA-sLASER using simultaneous interleaved acquisition for measuring GABA in the human brain at 7T.,0.7817000000000001,0.0504,0.17170000000000002,0.0634,12.0,3.0,9.0,29.33,4.49
GABA,2019_hong_14,5,10.1371/journal.pone.0223702,0.26,0.09,0.0,0.0,0.0,0.0,Healthy,GM,A comparison of sLASER and MEGA-sLASER using simultaneous interleaved acquisition for measuring GABA in the human brain at 7T.,0.6967,0.058899999999999994,0.20170000000000002,0.09449999999999999,12.0,3.0,9.0,29.33,4.49
GABA,2019_hong_14,6,10.1371/journal.pone.0223702,0.25,0.05,0.0,0.0,0.0,0.0,Healthy,GM,A comparison of sLASER and MEGA-sLASER using simultaneous interleaved acquisition for measuring GABA in the human brain at 7T.,0.6733,0.0689,0.2433,0.10890000000000001,12.0,3.0,9.0,29.33,4.49
GABA,2019_hong_14,7,10.1371/journal.pone.0223702,0.07,0.03,0.0,0.0,0.0,0.0,Healthy,WM,A comparison of sLASER and MEGA-sLASER using simultaneous interleaved acquisition for measuring GABA in the human brain at 7T.,0.275,0.0575,0.685,0.061900000000000004,12.0,3.0,9.0,29.33,4.49
GABA,2019_hong_14,10,10.1371/journal.pone.0223702,0.19,0.04,0.0,0.0,0.0,0.0,Healthy,GM,A comparison of sLASER and MEGA-sLASER using simultaneous interleaved acquisition for measuring GABA in the human brain at 7T.,0.7817000000000001,0.0504,0.17170000000000002,0.0634,12.0,3.0,9.0,29.33,4.49
GABA,2019_hong_14,11,10.1371/journal.pone.0223702,0.18,0.04,0.0,0.0,0.0,0.0,Healthy,GM,A comparison of sLASER and MEGA-sLASER using simultaneous interleaved acquisition for measuring GABA in the human brain at 7T.,0.6967,0.058899999999999994,0.20170000000000002,0.09449999999999999,12.0,3.0,9.0,29.33,4.49
GABA,2019_hong_14,12,10.1371/journal.pone.0223702,0.18,0.03,0.0,0.0,0.0,0.0,Healthy,GM,A comparison of sLASER and MEGA-sLASER using simultaneous interleaved acquisition for measuring GABA in the human brain at 7T.,0.6733,0.0689,0.2433,0.10890000000000001,12.0,3.0,9.0,29.33,4.49
GABA,2019_mikkelsen_191,1,10.1016/j.neuroimage.2019.02.059,0.0,0.0,3.33,0.2,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.6,0.05,0.26,0.04,12.0,7.0,5.0,23.92,4.81
GABA,2019_mikkelsen_191,3,10.1016/j.neuroimage.2019.02.059,0.0,0.0,2.92,0.26,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.6,0.03,0.29,0.02,7.0,2.0,5.0,23.43,5.47
GABA,2019_mikkelsen_191,4,10.1016/j.neuroimage.2019.02.059,0.0,0.0,3.31,0.39,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.6,0.03,0.28,0.02,12.0,6.0,6.0,25.58,4.48
GABA,2019_mikkelsen_191,5,10.1016/j.neuroimage.2019.02.059,0.0,0.0,2.96,0.2,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.65,0.05,0.26,0.01,12.0,5.0,7.0,25.5,3.73
GABA,2019_mikkelsen_191,10,10.1016/j.neuroimage.2019.02.059,0.0,0.0,3.3,0.37,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.6,0.03,0.27,0.04,12.0,6.0,6.0,25.08,3.23
GABA,2019_mikkelsen_191,14,10.1016/j.neuroimage.2019.02.059,0.0,0.0,3.03,0.25,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.63,0.03,0.27,0.02,8.0,3.0,5.0,23.13,2.36
GABA,2019_mikkelsen_191,16,10.1016/j.neuroimage.2019.02.059,0.0,0.0,3.1,0.22,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.63,0.03,0.27,0.03,12.0,6.0,6.0,23.58,3.73
GABA,2019_mikkelsen_191,17,10.1016/j.neuroimage.2019.02.059,0.0,0.0,3.59,0.33,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.61,0.04,0.28,0.03,12.0,5.0,7.0,23.25,1.96
GABA,2019_mikkelsen_191,23,10.1016/j.neuroimage.2019.02.059,0.0,0.0,4.28,0.48,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.61,0.03,0.29,0.02,12.0,6.0,6.0,27.67,2.77
GABA,2019_mikkelsen_191,30,10.1016/j.neuroimage.2019.02.059,0.0,0.0,4.4,0.61,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.6,0.05,0.26,0.04,12.0,7.0,5.0,23.92,4.81
GABA,2019_mikkelsen_191,33,10.1016/j.neuroimage.2019.02.059,0.0,0.0,2.95,0.93,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.6,0.03,0.28,0.02,12.0,6.0,6.0,25.58,4.48
GABA,2019_mikkelsen_191,34,10.1016/j.neuroimage.2019.02.059,0.0,0.0,2.23,0.54,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.65,0.05,0.26,0.01,12.0,5.0,7.0,25.5,3.73
GABA,2019_mikkelsen_191,39,10.1016/j.neuroimage.2019.02.059,0.0,0.0,3.47,0.33,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.6,0.03,0.27,0.04,12.0,6.0,6.0,25.08,3.23
GABA,2019_mikkelsen_191,43,10.1016/j.neuroimage.2019.02.059,0.0,0.0,2.61,0.32,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.63,0.03,0.27,0.02,8.0,3.0,5.0,23.13,2.36
GABA,2019_mikkelsen_191,45,10.1016/j.neuroimage.2019.02.059,0.0,0.0,2.87,0.55,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.63,0.03,0.27,0.03,12.0,6.0,6.0,23.58,3.73
GABA,2019_mikkelsen_191,46,10.1016/j.neuroimage.2019.02.059,0.0,0.0,5.7,0.4,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.61,0.04,0.28,0.03,12.0,5.0,7.0,23.25,1.96
GABA,2019_mikkelsen_191,52,10.1016/j.neuroimage.2019.02.059,0.0,0.0,3.22,0.55,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.61,0.03,0.29,0.02,12.0,6.0,6.0,27.67,2.77
GABA,2019_reid_45,1,10.1093/schbul/sbx190,0.0,0.0,0.93,0.18,0.0,0.0,Control,GM,7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.,0.7140000000000001,0.078,0.254,0.077,21.0,5.0,16.0,23.5,4.5
GABA,2019_sheth_248,3,10.1016/j.jad.2019.01.037,0.19,0.05,2.1,0.0,0.0,0.0,Control,GM,Reduced gamma-amino butyric acid (GABA) and glutamine in the anterior cingulate cortex (ACC) of veterans exposed to trauma.,0.703,0.03,0.297,0.037000000000000005,28.0,4.0,24.0,35.4,8.6
GABA,2019_strasser_29,1,10.1016/j.euroneuro.2018.12.015,0.0,0.0,2.22,0.53,2.22,0.53,Healthy,GM,Nucleus accumbens neurochemistry in human anxiety: A 7T H-1-MRS study,0.85,0.04,0.12,0.05,38.0,0.0,38.0,25.0,20-30
GABA,2019_wang_76,6,10.1001/jamapsychiatry.2018.3637,0.0,0.0,1.72,0.15,0.0,0.0,Control,GM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.725,0.12,0.17,0.09,91.0,49.0,42.0,23.3,3.9
GABA,2019_wang_76,7,10.1001/jamapsychiatry.2018.3637,0.0,0.0,1.65,0.22,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.1,0.12,0.88,0.14,91.0,49.0,42.0,23.3,3.9
GABA,2019_wang_76,9,10.1001/jamapsychiatry.2018.3637,0.0,0.0,1.5,0.23,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.27,0.15,0.75,0.11,91.0,49.0,42.0,23.3,3.9
GABA,2019_wang_76,10,10.1001/jamapsychiatry.2018.3637,0.0,0.0,2.0,0.18,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.3,0.18,0.66,0.2,91.0,49.0,42.0,23.3,3.9
GABA,2020_sheth_123,2,10.1152/jn.00765.2019,0.0,0.0,0.41,0.05,0.0,0.0,Control,GM,Increased myoinositol in the anterior cingulate cortex of veterans with a history of traumatic brain injury: a proton magnetic resonance spectroscopy study.,0.6990000000000001,0.028999999999999998,0.3,0.028999999999999998,26.0,0.0,0.0,34.3,9.2
GABA,2021_steinegger_26,1,10.1111/adb.13027,0.0,0.0,4.38,0.75,4.38,0.75,Control,GM,Neurometabolic alterations in the nucleus accumbens of smokers assessed with H-1 magnetic resonance spectroscopy: The role of glutamate and neuroinflammation,0.8075,0.058899999999999994,0.1925,0.058899999999999994,25.0,0.0,20.0,26.3,4.27
Glc,2017_suri_152,1,10.1016/j.neuroimage.2017.03.031,0.431,0.026,0.0,0.0,0.0,0.0,Control,GM,Effect of age and the APOE gene on metabolite concentrations in the posterior cingulate cortex.,0.6,0.03,0.23,0.03,30.0,13.0,17.0,23.87,4.95
Gln,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,3.18,0.3298,3.18,0.3298,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
Gln,2017_suri_152,1,10.1016/j.neuroimage.2017.03.031,0.258,0.016,0.0,0.0,0.0,0.0,Control,GM,Effect of age and the APOE gene on metabolite concentrations in the posterior cingulate cortex.,0.6,0.03,0.23,0.03,30.0,13.0,17.0,23.87,4.95
Gln,2018_evans_43,1,10.1038/s41386-018-0057-1,0.29,0.02,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
Gln,2018_evans_43,2,10.1038/s41386-018-0057-1,0.31,0.03,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
Gln,2018_evans_43,3,10.1038/s41386-018-0057-1,0.28,0.03,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
Gln,2018_sheth_276,3,10.1016/j.pscychresns.2018.04.004,0.0,0.0,0.48,0.05,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.7021999999999999,0.03,0.2978,0.03,24.0,5.0,19.0,36.2,9.7
Gln,2018_sheth_276,4,10.1016/j.pscychresns.2018.04.004,0.0,0.0,0.55,0.05,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.6139,0.043,0.3861,0.043,24.0,5.0,19.0,36.2,9.7
Gln,2018_white_43,2,10.1038/s41386-018-0027-7,0.0,0.0,4.59,0.85,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
Gln,2018_white_43,3,10.1038/s41386-018-0027-7,0.0,0.0,4.42,0.95,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
Gln,2018_white_43,1,10.1038/s41386-018-0027-7,0.0,0.0,4.41,0.87,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
Gln,2019_reid_45,1,10.1093/schbul/sbx190,0.0,0.0,1.91,0.23,0.0,0.0,Control,GM,7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.,0.7140000000000001,0.078,0.254,0.077,21.0,5.0,16.0,23.5,4.5
Gln,2019_sheth_248,3,10.1016/j.jad.2019.01.037,0.27,0.05,0.58,0.0,0.0,0.0,Control,GM,Reduced gamma-amino butyric acid (GABA) and glutamine in the anterior cingulate cortex (ACC) of veterans exposed to trauma.,0.703,0.03,0.297,0.037000000000000005,28.0,4.0,24.0,35.4,8.6
Gln,2019_strasser_29,1,10.1016/j.euroneuro.2018.12.015,0.0,0.0,4.45,1.05,4.45,1.05,Healthy,GM,Nucleus accumbens neurochemistry in human anxiety: A 7T H-1-MRS study,0.85,0.04,0.12,0.05,38.0,0.0,38.0,25.0,20-30
Gln,2019_wang_76,6,10.1001/jamapsychiatry.2018.3637,0.0,0.0,1.8,0.25,0.0,0.0,Control,GM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.725,0.12,0.17,0.09,91.0,49.0,42.0,23.3,3.9
Gln,2019_wang_76,7,10.1001/jamapsychiatry.2018.3637,0.0,0.0,1.0,0.15,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.1,0.12,0.88,0.14,91.0,49.0,42.0,23.3,3.9
Gln,2019_wang_76,9,10.1001/jamapsychiatry.2018.3637,0.0,0.0,1.52,0.18,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.27,0.15,0.75,0.11,91.0,49.0,42.0,23.3,3.9
Gln,2019_wang_76,10,10.1001/jamapsychiatry.2018.3637,0.0,0.0,1.4,0.8,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.3,0.18,0.66,0.2,91.0,49.0,42.0,23.3,3.9
Gln,2019_wiegers_62,1,10.1007/s00125-019-4862-9,0.0,0.0,1.32,0.44,1.32,0.44,Control,WM,Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status.,0.265,0.042,0.713,0.047,13.0,7.0,6.0,25.5,5.5
Gln,2020_kumar_25,1,10.1038/s41380-018-0104-7,0.0,0.0,1.66,0.31,1.66,0.31,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.743,0.067,0.111,0.064,45.0,16.0,29.0,27.89,7.54
Gln,2020_kumar_25,2,10.1038/s41380-018-0104-7,0.0,0.0,1.2,0.23,1.2,0.23,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.637,0.046,0.285,0.051,45.0,16.0,29.0,27.89,7.54
Gln,2020_kumar_25,3,10.1038/s41380-018-0104-7,0.0,0.0,1.57,0.28,1.57,0.28,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.6759999999999999,0.051,0.226,0.085,45.0,16.0,29.0,27.89,7.54
Gln,2020_sheth_123,2,10.1152/jn.00765.2019,0.0,0.0,0.5,0.04,0.0,0.0,Control,GM,Increased myoinositol in the anterior cingulate cortex of veterans with a history of traumatic brain injury: a proton magnetic resonance spectroscopy study.,0.6990000000000001,0.028999999999999998,0.3,0.028999999999999998,26.0,0.0,0.0,34.3,9.2
Gln,2020_tran_30,1,10.1111/jon.12728,0.6,0.13,0.0,0.0,0.0,0.0,Control,GM,Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis.,0.0,0.0,0.0,0.0,16.0,6.0,10.0,57.8,11.7
Gln,2020_tran_30,2,10.1111/jon.12728,0.41,0.98,0.0,0.0,0.0,0.0,Control,WM,Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis.,0.0,0.0,0.0,0.0,16.0,6.0,10.0,57.8,11.7
Gln,2021_bednarik_15,1,10.3389/fnins.2021.609485,0.0,0.0,2.83,0.21,2.83,0.21,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7240000000000001,0.0178,0.18600000000000003,0.031,12.0,0.0,12.0,26.0,5
Gln,2021_bednarik_15,2,10.3389/fnins.2021.609485,0.0,0.0,2.43,0.21,2.43,0.21,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7340000000000001,0.018000000000000002,0.17800000000000002,0.032,12.0,0.0,12.0,26.0,5
Gln,2021_gajdosik_34,1,10.1002/nbm.4538,0.0,0.0,2.0,1.3,2.0,1.3,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,2.0,1.0,32.5,10.2
Gln,2021_gajdosik_34,2,10.1002/nbm.4538,0.0,0.0,2.7,0.8,2.7,0.8,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,1.0,2.0,32.5,10.2
Gln,2021_godlewska_11,4,10.1038/s41398-021-01477-6,0.0,0.0,3.93,0.467,0.0,0.0,Control,GM,Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7T.,0.8340000000000001,0.013000000000000001,0.09300000000000001,0.3,18.0,0.0,18.0,27.1,0.8
Gln,2021_godlewska_11,5,10.1038/s41398-021-01477-6,0.0,0.0,2.8,0.424,0.0,0.0,Control,WM,Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7T.,0.377,0.017,0.607,0.015,18.0,0.0,18.0,27.1,0.8
Gln,2021_godlewska_11,6,10.1038/s41398-021-01477-6,0.0,0.0,3.01,0.6,0.0,0.0,Control,WM,Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7T.,0.345,0.018000000000000002,0.654,0.018000000000000002,18.0,0.0,18.0,27.1,0.8
Gln,2021_steinegger_26,1,10.1111/adb.13027,0.0,0.0,5.12,1.87,5.12,1.87,Control,GM,Neurometabolic alterations in the nucleus accumbens of smokers assessed with H-1 magnetic resonance spectroscopy: The role of glutamate and neuroinflammation,0.8075,0.058899999999999994,0.1925,0.058899999999999994,25.0,0.0,20.0,26.3,4.27
Glu,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,10.74,0.6185,10.74,0.6185,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
Glu,2017_suri_152,1,10.1016/j.neuroimage.2017.03.031,1.243,0.0745,0.0,0.0,0.0,0.0,Control,GM,Effect of age and the APOE gene on metabolite concentrations in the posterior cingulate cortex.,0.6,0.03,0.23,0.03,30.0,13.0,17.0,23.87,4.95
Glu,2018_burger_185,17,10.1016/j.drugalcdep.2017.11.029,1.165,0.17,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
Glu,2018_burger_185,18,10.1016/j.drugalcdep.2017.11.029,1.247,0.232,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
Glu,2018_caravaggio_28,1,10.1016/j.euroneuro.2017.12.002,0.0,0.0,8.88,1.31,0.0,0.0,Healthy,WM,Reduced insulin sensitivity may be related to less striatal glutamate: An (1)H-MRS study in healthy non-obese humans.,0.2921,0.0391,0.6297999999999999,0.0621,17.0,9.0,8.0,28.35,9.53
Glu,2018_caravaggio_28,2,10.1016/j.euroneuro.2017.12.002,0.0,0.0,8.41,1.81,0.0,0.0,Healthy,WM,Reduced insulin sensitivity may be related to less striatal glutamate: An (1)H-MRS study in healthy non-obese humans.,0.2465,0.028399999999999998,0.6658,0.06709999999999999,17.0,9.0,8.0,28.35,9.53
Glu,2018_egerton_23,7,10.1038/s41380-018-0082-9,1.27,0.16,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,8,10.1038/s41380-018-0082-9,1.42,0.08,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,9,10.1038/s41380-018-0082-9,1.3,0.11,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,10,10.1038/s41380-018-0082-9,1.0,0.18,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,11,10.1038/s41380-018-0082-9,1.28,0.19,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,12,10.1038/s41380-018-0082-9,1.04,0.19,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,1,10.1038/s41380-018-0082-9,1.33,0.15,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,2,10.1038/s41380-018-0082-9,1.36,0.11,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,3,10.1038/s41380-018-0082-9,1.34,0.12,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,4,10.1038/s41380-018-0082-9,1.07,0.12,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,5,10.1038/s41380-018-0082-9,1.19,0.17,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,6,10.1038/s41380-018-0082-9,1.02,0.25,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
Glu,2018_evans_43,1,10.1038/s41386-018-0057-1,1.25,0.02,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
Glu,2018_evans_43,2,10.1038/s41386-018-0057-1,1.28,0.03,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
Glu,2018_evans_43,3,10.1038/s41386-018-0057-1,1.27,0.03,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
Glu,2018_lynn_172,1,10.1016/j.neuroimage.2018.01.069,0.0,0.0,11.9,1.1,11.9,1.1,Control,WM,Differences in steady-state glutamate levels and variability between 'non-task-active' conditions: Evidence from (1)H fMRS of the prefrontal cortex.,0.368,0.038,0.608,0.045,16.0,7.0,9.0,24.3,3.5
Glu,2018_plitman_273,2,10.1016/j.pscychresns.2018.01.004,0.0,0.0,11.69,1.19,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
Glu,2018_plitman_273,5,10.1016/j.pscychresns.2018.01.004,0.0,0.0,11.92,1.45,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
Glu,2018_plitman_273,6,10.1016/j.pscychresns.2018.01.004,0.0,0.0,12.61,1.62,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
Glu,2018_shakory_43,1,10.1038/s41386-018-0163-0,0.0,0.0,10.492,1.377,0.0,0.0,Control,GM,Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.,0.6,0.11,0.35,0.091,31.0,18.0,13.0,22.2,3.1
Glu,2018_shakory_43,8,10.1038/s41386-018-0163-0,0.0,0.0,10.41,1.47,0.0,0.0,Control,GM,Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.,0.6,0.11,0.35,0.091,18.0,0.0,0.0,22.2,3.1
Glu,2018_shakory_43,9,10.1038/s41386-018-0163-0,0.0,0.0,10.65,1.34,0.0,0.0,Control,GM,Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.,0.6,0.11,0.35,0.091,13.0,0.0,0.0,22.2,3.1
Glu,2018_sheth_276,3,10.1016/j.pscychresns.2018.04.004,0.0,0.0,2.34,0.12,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.7021999999999999,0.03,0.2978,0.03,24.0,5.0,19.0,36.2,9.7
Glu,2018_sheth_276,4,10.1016/j.pscychresns.2018.04.004,0.0,0.0,2.06,0.06,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.6139,0.043,0.3861,0.043,24.0,5.0,19.0,36.2,9.7
Glu,2018_soeiro-de-souza_3,1,10.1016/j.bpsc.2018.02.007,0.99,0.11,0.0,0.0,0.0,0.0,Control,GM,Anterior Cingulate Cortex Glutamatergic Metabolites and Mood Stabilizers in Euthymic Bipolar I Disorder Patients: A Proton Magnetic Resonance Spectroscopy Study.,0.6308,0.04,0.175,0.03,80.0,42.0,38.0,28.13,8.19
Glu,2018_tiwari_80,1,10.1002/mrm.27142,0.0,0.0,9.2,0.6,9.2,0.6,Healthy,GM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.61,0.03,0.23,0.02,6.0,3.0,3.0,27.0,5
Glu,2018_tiwari_80,2,10.1002/mrm.27142,0.0,0.0,6.44,0.44,6.44,0.44,Healthy,WM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.16,0.05,0.81,0.08,6.0,3.0,3.0,27.0,5
Glu,2018_tiwari_80,3,10.1002/mrm.27142,0.0,0.0,10.3,0.9,10.3,0.9,Healthy,WM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.0,0.0,0.0,0.0,6.0,3.0,3.0,27.0,5
Glu,2018_tiwari_80,5,10.1002/mrm.27142,0.0,0.0,9.15,0.81,9.15,0.81,Healthy,GM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.0,0.0,0.0,0.0,6.0,3.0,3.0,27.0,5
Glu,2018_tiwari_80,6,10.1002/mrm.27142,0.0,0.0,7.19,0.55,7.19,0.55,Healthy,GM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.0,0.0,0.0,0.0,6.0,3.0,3.0,27.0,5
Glu,2018_veeramuthu_25,3,10.1016/j.acra.2018.01.005,1.567,0.215,2.736,0.272,0.0,0.0,Control,WM,Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI): An In Vivo Proton Magnetic Resonance Spectroscopy (1H-MRS) Study.,0.0,0.0,0.0,0.0,13.0,5.0,8.0,27.15,4.88
Glu,2018_white_43,2,10.1038/s41386-018-0027-7,0.0,0.0,9.32,1.01,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
Glu,2018_white_43,3,10.1038/s41386-018-0027-7,0.0,0.0,8.8,1.08,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
Glu,2018_white_43,1,10.1038/s41386-018-0027-7,0.0,0.0,8.62,0.84,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
Glu,2019_bossong_76,1,10.1001/jamapsychiatry.2018.3252,0.0,0.0,8.31,1.12,8.31,1.12,Control,GM,Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis.,0.64,0.07,0.33,0.08,30.0,16.0,14.0,24.7,3.8
Glu,2019_jelen_29,7,10.1016/j.euroneuro.2018.12.005,0.86,0.1,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Glu,2019_jelen_29,10,10.1016/j.euroneuro.2018.12.005,0.97,0.07,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Glu,2019_jelen_29,1,10.1016/j.euroneuro.2018.12.005,0.9,0.13,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Glu,2019_jelen_29,10,10.1016/j.euroneuro.2018.12.005,0.92,0.11,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Glu,2019_reid_45,1,10.1093/schbul/sbx190,0.0,0.0,6.93,0.5,0.0,0.0,Control,GM,7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.,0.7140000000000001,0.078,0.254,0.077,21.0,5.0,16.0,23.5,4.5
Glu,2019_sheth_248,3,10.1016/j.jad.2019.01.037,1.13,0.16,2.37,0.0,0.0,0.0,Control,GM,Reduced gamma-amino butyric acid (GABA) and glutamine in the anterior cingulate cortex (ACC) of veterans exposed to trauma.,0.703,0.03,0.297,0.037000000000000005,28.0,4.0,24.0,35.4,8.6
Glu,2019_strasser_29,1,10.1016/j.euroneuro.2018.12.015,0.0,0.0,9.79,1.09,9.79,1.09,Healthy,GM,Nucleus accumbens neurochemistry in human anxiety: A 7T H-1-MRS study,0.85,0.04,0.12,0.05,38.0,0.0,38.0,25.0,20-30
Glu,2019_wang_76,6,10.1001/jamapsychiatry.2018.3637,0.0,0.0,8.2,1.6,0.0,0.0,Control,GM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.725,0.12,0.17,0.09,91.0,49.0,42.0,23.3,3.9
Glu,2019_wang_76,7,10.1001/jamapsychiatry.2018.3637,0.0,0.0,5.1,0.8,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.1,0.12,0.88,0.14,91.0,49.0,42.0,23.3,3.9
Glu,2019_wang_76,9,10.1001/jamapsychiatry.2018.3637,0.0,0.0,5.5,1.2,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.27,0.15,0.75,0.11,91.0,49.0,42.0,23.3,3.9
Glu,2019_wang_76,10,10.1001/jamapsychiatry.2018.3637,0.0,0.0,6.3,1.6,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.3,0.18,0.66,0.2,91.0,49.0,42.0,23.3,3.9
Glu,2019_wiegers_62,1,10.1007/s00125-019-4862-9,0.0,0.0,6.1,0.74,6.1,0.74,Control,WM,Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status.,0.265,0.042,0.713,0.047,13.0,7.0,6.0,25.5,5.5
Glu,2020_bell_34,1,10.1002/nbm.4245,0.0,0.0,15.5,2.0,15.5,2.0,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,2,10.1002/nbm.4245,0.0,0.0,13.1,1.5,13.1,1.5,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,3,10.1002/nbm.4245,0.0,0.0,13.8,3.0,13.8,3.0,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,4,10.1002/nbm.4245,0.0,0.0,13.8,1.2,13.8,1.2,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,5,10.1002/nbm.4245,0.0,0.0,11.8,3.0,11.8,3.0,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,6,10.1002/nbm.4245,0.0,0.0,9.6,1.0,9.6,1.0,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,7,10.1002/nbm.4245,0.0,0.0,5.3,3.0,5.3,3.0,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,8,10.1002/nbm.4245,0.0,0.0,6.1,0.5,6.1,0.5,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,9,10.1002/nbm.4245,0.0,0.0,2.6,3.0,2.6,3.0,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,10,10.1002/nbm.4245,0.0,0.0,2.8,0.4,2.8,0.4,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_kumar_25,1,10.1038/s41380-018-0104-7,0.0,0.0,6.21,0.81,6.21,0.81,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.743,0.067,0.111,0.064,45.0,16.0,29.0,27.89,7.54
Glu,2020_kumar_25,2,10.1038/s41380-018-0104-7,0.0,0.0,5.4,0.51,5.4,0.51,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.637,0.046,0.285,0.051,45.0,16.0,29.0,27.89,7.54
Glu,2020_kumar_25,3,10.1038/s41380-018-0104-7,0.0,0.0,6.44,0.51,6.44,0.51,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.6759999999999999,0.051,0.226,0.085,45.0,16.0,29.0,27.89,7.54
Glu,2020_lind_40,1,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,9.62,0.36,9.62,0.36,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.64669,0.0,0.23431000000000002,0.0,20.0,10.0,10.0,22.6,2.37
Glu,2020_lind_40,4,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,7.07,0.55,7.07,0.55,Control,WM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.29254,0.0,0.66486,0.0,20.0,10.0,10.0,22.6,2.37
Glu,2020_lind_40,10,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,6.04,0.7,6.04,0.7,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.6731999999999999,0.0,0.3268,0.0,20.0,10.0,10.0,22.6,2.37
Glu,2020_poletti_11,2,10.3389/fpsyt.2020.590095,0.0,0.0,7.68,1.04,0.0,0.0,Control,GM,Proinflammatory Cytokines Predict Brain Metabolite Concentrations in the Anterior Cingulate Cortex of Patients With Bipolar Disorder,0.7745000000000001,0.0795,0.8101999999999999,0.10279999999999999,49.0,21.0,28.0,33.7,11.14
Glu,2020_sheth_123,2,10.1152/jn.00765.2019,0.0,0.0,2.26,0.13,0.0,0.0,Control,GM,Increased myoinositol in the anterior cingulate cortex of veterans with a history of traumatic brain injury: a proton magnetic resonance spectroscopy study.,0.6990000000000001,0.028999999999999998,0.3,0.028999999999999998,26.0,0.0,0.0,34.3,9.2
Glu,2020_tran_30,1,10.1111/jon.12728,1.5,0.09,0.0,0.0,0.0,0.0,Control,GM,Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis.,0.0,0.0,0.0,0.0,16.0,6.0,10.0,57.8,11.7
Glu,2020_tran_30,2,10.1111/jon.12728,1.23,0.15,0.0,0.0,0.0,0.0,Control,WM,Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis.,0.0,0.0,0.0,0.0,16.0,6.0,10.0,57.8,11.7
Glu,2021_bednarik_15,1,10.3389/fnins.2021.609485,0.0,0.0,10.1,0.28,10.1,0.28,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7240000000000001,0.0178,0.18600000000000003,0.031,12.0,0.0,12.0,26.0,5
Glu,2021_bednarik_15,2,10.3389/fnins.2021.609485,0.0,0.0,9.87,0.28,9.87,0.28,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7340000000000001,0.018000000000000002,0.17800000000000002,0.032,12.0,0.0,12.0,26.0,5
Glu,2021_gajdosik_34,1,10.1002/nbm.4538,0.0,0.0,9.2,2.4,9.2,2.4,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,2.0,1.0,32.5,10.2
Glu,2021_gajdosik_34,2,10.1002/nbm.4538,0.0,0.0,9.2,1.1,9.2,1.1,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,1.0,2.0,32.5,10.2
Glu,2021_godlewska_11,4,10.1038/s41398-021-01477-6,0.0,0.0,12.24,0.721,0.0,0.0,Control,GM,Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7T.,0.8340000000000001,0.013000000000000001,0.09300000000000001,0.3,18.0,0.0,18.0,27.1,0.8
Glu,2021_godlewska_11,5,10.1038/s41398-021-01477-6,0.0,0.0,9.0,2.758,0.0,0.0,Control,WM,Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7T.,0.377,0.017,0.607,0.015,18.0,0.0,18.0,27.1,0.8
Glu,2021_godlewska_11,6,10.1038/s41398-021-01477-6,0.0,0.0,9.67,0.96,0.0,0.0,Control,WM,Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7T.,0.345,0.018000000000000002,0.654,0.018000000000000002,18.0,0.0,18.0,27.1,0.8
Glu,2021_steinegger_26,1,10.1111/adb.13027,0.0,0.0,11.89,1.28,11.89,1.28,Control,GM,Neurometabolic alterations in the nucleus accumbens of smokers assessed with H-1 magnetic resonance spectroscopy: The role of glutamate and neuroinflammation,0.8075,0.058899999999999994,0.1925,0.058899999999999994,25.0,0.0,20.0,26.3,4.27
Gly,2021_steinegger_26,1,10.1111/adb.13027,0.0,0.0,6.34,2.0,6.34,2.0,Control,GM,Neurometabolic alterations in the nucleus accumbens of smokers assessed with H-1 magnetic resonance spectroscopy: The role of glutamate and neuroinflammation,0.8075,0.058899999999999994,0.1925,0.058899999999999994,25.0,0.0,20.0,26.3,4.27
GPC,2017_bustillo_43,1,10.1093/schbul/sbw122,0.0,0.0,6.5,1.1,6.5,1.1,Control,WM,Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample.,0.37,0.17,0.63,0.0,97.0,69.0,28.0,37.1,12.3
GPC,2018_caravaggio_28,1,10.1016/j.euroneuro.2017.12.002,0.0,0.0,2.14,0.25,0.0,0.0,Healthy,WM,Reduced insulin sensitivity may be related to less striatal glutamate: An (1)H-MRS study in healthy non-obese humans.,0.2921,0.0391,0.6297999999999999,0.0621,17.0,9.0,8.0,28.35,9.53
GPC,2018_caravaggio_28,2,10.1016/j.euroneuro.2017.12.002,0.0,0.0,2.09,0.28,0.0,0.0,Healthy,WM,Reduced insulin sensitivity may be related to less striatal glutamate: An (1)H-MRS study in healthy non-obese humans.,0.2465,0.028399999999999998,0.6658,0.06709999999999999,17.0,9.0,8.0,28.35,9.53
GPC,2018_chiu_193,4,10.1016/j.schres.2017.07.021,0.0,0.0,1.83,0.24,1.83,0.24,Control,GM,In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study.,0.6076,0.0858,0.2432,0.0821,14.0,5.0,9.0,27.71,5.88
GPC,2018_evans_43,1,10.1038/s41386-018-0057-1,0.29,0.02,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
GPC,2018_evans_43,2,10.1038/s41386-018-0057-1,0.3,0.03,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
GPC,2018_evans_43,3,10.1038/s41386-018-0057-1,0.28,0.03,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
GPC,2018_sheth_276,3,10.1016/j.pscychresns.2018.04.004,0.0,0.0,0.61,0.03,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.7021999999999999,0.03,0.2978,0.03,24.0,5.0,19.0,36.2,9.7
GPC,2018_sheth_276,4,10.1016/j.pscychresns.2018.04.004,0.0,0.0,0.43,0.01,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.6139,0.043,0.3861,0.043,24.0,5.0,19.0,36.2,9.7
GPC,2018_soeiro-de-souza_241,1,10.1016/j.jad.2018.08.039,0.0,0.0,2.763,0.396,2.763,0.396,Control,GM,Lithium-associated anterior cingulate neurometabolic profile in euthymic Bipolar I disorder: A (1)H-MRS study.,0.6273,0.04,0.1762,0.04,79.0,85.0,44.0,28.4,8.1
GPC,2018_veeramuthu_25,3,10.1016/j.acra.2018.01.005,0.374,0.049,0.66,0.109,0.0,0.0,Control,WM,Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI): An In Vivo Proton Magnetic Resonance Spectroscopy (1H-MRS) Study.,0.0,0.0,0.0,0.0,13.0,5.0,8.0,27.15,4.88
GPC,2018_white_43,2,10.1038/s41386-018-0027-7,0.0,0.0,1.91,0.19,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
GPC,2018_white_43,3,10.1038/s41386-018-0027-7,0.0,0.0,1.82,0.2,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
GPC,2018_white_43,1,10.1038/s41386-018-0027-7,0.0,0.0,1.8,0.19,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
GPC,2019_bossong_76,1,10.1001/jamapsychiatry.2018.3252,0.0,0.0,2.3,0.4,2.3,0.4,Control,GM,Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis.,0.64,0.07,0.33,0.08,30.0,16.0,14.0,24.7,3.8
GPC,2019_bustillo_246,1,10.1016/j.jad.2018.12.064,0.0,0.0,3.2,0.6,3.2,0.6,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
GPC,2019_bustillo_246,2,10.1016/j.jad.2018.12.064,0.0,0.0,3.1,0.4,3.1,0.4,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
GPC,2019_bustillo_246,3,10.1016/j.jad.2018.12.064,0.0,0.0,3.5,0.6,3.5,0.6,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
GPC,2019_bustillo_246,4,10.1016/j.jad.2018.12.064,0.0,0.0,3.4,0.4,3.4,0.4,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
GPC,2019_davitz_50,9,10.1002/jmri.26718,0.0,0.0,1.8,0.3,1.8,0.3,Control,WM,Quantitative multivoxel proton MR spectroscopy for the identification of white matter abnormalities in mild traumatic brain injury: Comparison between regional and global analysis.,0.0,0.0,0.0,0.0,12.0,4.0,8.0,34.0,0
GPC,2019_davitz_50,10,10.1002/jmri.26718,0.0,0.0,1.5,0.3,1.5,0.3,Control,WM,Quantitative multivoxel proton MR spectroscopy for the identification of white matter abnormalities in mild traumatic brain injury: Comparison between regional and global analysis.,0.0,0.0,0.0,0.0,12.0,4.0,8.0,34.0,0
GPC,2019_pflugrad_14,12,10.1371/journal.pone.0221626,0.0,0.0,1.08,0.15,0.0,0.0,Control,WM,Cerebral metabolite alterations in patients with posttransplant encephalopathy after liver transplantation,0.0,0.0,0.0,0.0,20.0,14.0,6.0,47.8,10.8
GPC,2020_blest-hopley_25,2,10.1111/adb.12827,0.0,0.0,2.444,0.302,0.0,0.0,Control,GM,Adolescent-onset heavy cannabis use associated with significantly reduced glial but not neuronal markers and glutamate levels in the hippocampus.,0.6365,0.058,0.3099,0.098,21.0,12.0,9.0,24.24,4.11
GPC,2021_gajdosik_34,1,10.1002/nbm.4538,0.0,0.0,1.6,0.2,1.6,0.2,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,2.0,1.0,32.5,10.2
GPC,2021_gajdosik_34,2,10.1002/nbm.4538,0.0,0.0,1.8,0.3,1.8,0.3,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,1.0,2.0,32.5,10.2
GPC,2021_gramegna_8,6,10.1002/acn3.51329,0.17,0.02,0.0,0.0,0.0,0.0,Control,WM,Brain MRS correlates with mitochondrial dysfunction biomarkers in MELAS-associated mtDNA mutations,0.0,0.0,0.0,0.0,39.0,0.0,0.0,42.2,0
GSH,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,1.07,0.0825,1.07,0.0825,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
GSH,2017_suri_152,1,10.1016/j.neuroimage.2017.03.031,0.139,0.008,0.0,0.0,0.0,0.0,Control,GM,Effect of age and the APOE gene on metabolite concentrations in the posterior cingulate cortex.,0.6,0.03,0.23,0.03,30.0,13.0,17.0,23.87,4.95
GSH,2018_evans_43,1,10.1038/s41386-018-0057-1,0.24,0.02,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
GSH,2018_evans_43,2,10.1038/s41386-018-0057-1,0.24,0.03,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
GSH,2018_evans_43,3,10.1038/s41386-018-0057-1,0.25,0.03,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
GSH,2019_monnig_54,1,10.1093/alcalc/agz062,0.349,0.048,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolites on the Descending Limb of Acute Alcohol: A Preliminary 1H MRS Study.,0.0,0.0,0.0,0.0,13.0,8.0,5.0,26.4,2.8
GSH,2019_reid_45,1,10.1093/schbul/sbx190,0.0,0.0,0.75,0.1,0.0,0.0,Control,GM,7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.,0.7140000000000001,0.078,0.254,0.077,21.0,5.0,16.0,23.5,4.5
GSH,2019_wang_76,6,10.1001/jamapsychiatry.2018.3637,0.0,0.0,1.65,0.22,0.0,0.0,Control,GM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.725,0.12,0.17,0.09,91.0,49.0,42.0,23.3,3.9
GSH,2019_wang_76,7,10.1001/jamapsychiatry.2018.3637,0.0,0.0,1.2,0.2,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.1,0.12,0.88,0.14,91.0,49.0,42.0,23.3,3.9
GSH,2019_wang_76,9,10.1001/jamapsychiatry.2018.3637,0.0,0.0,1.21,0.23,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.27,0.15,0.75,0.11,91.0,49.0,42.0,23.3,3.9
GSH,2019_wang_76,10,10.1001/jamapsychiatry.2018.3637,0.0,0.0,1.42,0.23,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.3,0.18,0.66,0.2,91.0,49.0,42.0,23.3,3.9
GSH,2019_wiegers_62,1,10.1007/s00125-019-4862-9,0.0,0.0,0.94,0.12,0.94,0.12,Control,WM,Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status.,0.265,0.042,0.713,0.047,13.0,7.0,6.0,25.5,5.5
GSH,2020_kumar_25,1,10.1038/s41380-018-0104-7,0.0,0.0,1.75,0.31,1.75,0.31,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.743,0.067,0.111,0.064,45.0,16.0,29.0,27.89,7.54
GSH,2020_kumar_25,2,10.1038/s41380-018-0104-7,0.0,0.0,1.5,0.17,1.5,0.17,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.637,0.046,0.285,0.051,45.0,16.0,29.0,27.89,7.54
GSH,2020_kumar_25,3,10.1038/s41380-018-0104-7,0.0,0.0,1.72,0.2,1.72,0.2,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.6759999999999999,0.051,0.226,0.085,45.0,16.0,29.0,27.89,7.54
GSH,2020_poletti_11,2,10.3389/fpsyt.2020.590095,0.0,0.0,1.54,0.16,0.0,0.0,Control,GM,Proinflammatory Cytokines Predict Brain Metabolite Concentrations in the Anterior Cingulate Cortex of Patients With Bipolar Disorder,0.7745000000000001,0.0795,0.8101999999999999,0.10279999999999999,49.0,21.0,28.0,33.7,11.14
GSH,2021_bednarik_15,1,10.3389/fnins.2021.609485,0.0,0.0,1.7,0.1,1.7,0.1,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7240000000000001,0.0178,0.18600000000000003,0.031,12.0,0.0,12.0,26.0,5
GSH,2021_bednarik_15,2,10.3389/fnins.2021.609485,0.0,0.0,1.7,0.1,1.7,0.1,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7340000000000001,0.018000000000000002,0.17800000000000002,0.032,12.0,0.0,12.0,26.0,5
GSH,2021_godlewska_11,4,10.1038/s41398-021-01477-6,0.0,0.0,1.29,0.255,0.0,0.0,Control,GM,Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7T.,0.8340000000000001,0.013000000000000001,0.09300000000000001,0.3,18.0,0.0,18.0,27.1,0.8
GSH,2021_godlewska_11,5,10.1038/s41398-021-01477-6,0.0,0.0,1.3,0.255,0.0,0.0,Control,WM,Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7T.,0.377,0.017,0.607,0.015,18.0,0.0,18.0,27.1,0.8
GSH,2021_godlewska_11,6,10.1038/s41398-021-01477-6,0.0,0.0,1.43,2.88,0.0,0.0,Control,WM,Brain glutamate concentration in men with early psychosis: a magnetic resonance spectroscopy case-control study at 7T.,0.345,0.018000000000000002,0.654,0.018000000000000002,18.0,0.0,18.0,27.1,0.8
Lac,2020_lind_40,1,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,0.66,0.23,0.66,0.23,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.64669,0.0,0.23431000000000002,0.0,20.0,10.0,10.0,22.6,2.37
Lac,2021_gajdosik_34,1,10.1002/nbm.4538,0.0,0.0,2.6,0.6,2.6,0.6,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,2.0,1.0,32.5,10.2
Lac,2021_gajdosik_34,2,10.1002/nbm.4538,0.0,0.0,2.4,0.9,2.4,0.9,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,1.0,2.0,32.5,10.2
mI,2017_bustillo_43,1,10.1093/schbul/sbw122,0.0,0.0,13.1,2.2,13.1,2.2,Control,WM,Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample.,0.37,0.17,0.63,0.0,97.0,69.0,28.0,37.1,12.3
mI,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,7.12,0.5772,7.12,0.5772,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
mI,2017_suri_152,1,10.1016/j.neuroimage.2017.03.031,0.749,0.049,0.0,0.0,0.0,0.0,Control,GM,Effect of age and the APOE gene on metabolite concentrations in the posterior cingulate cortex.,0.6,0.03,0.23,0.03,30.0,13.0,17.0,23.87,4.95
mI,2018_burger_185,17,10.1016/j.drugalcdep.2017.11.029,0.988,0.108,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
mI,2018_burger_185,18,10.1016/j.drugalcdep.2017.11.029,0.955,0.125,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
mI,2018_caravaggio_28,1,10.1016/j.euroneuro.2017.12.002,0.0,0.0,4.78,1.05,0.0,0.0,Healthy,WM,Reduced insulin sensitivity may be related to less striatal glutamate: An (1)H-MRS study in healthy non-obese humans.,0.2921,0.0391,0.6297999999999999,0.0621,17.0,9.0,8.0,28.35,9.53
mI,2018_caravaggio_28,2,10.1016/j.euroneuro.2017.12.002,0.0,0.0,4.33,1.39,0.0,0.0,Healthy,WM,Reduced insulin sensitivity may be related to less striatal glutamate: An (1)H-MRS study in healthy non-obese humans.,0.2465,0.028399999999999998,0.6658,0.06709999999999999,17.0,9.0,8.0,28.35,9.53
mI,2018_chiu_193,4,10.1016/j.schres.2017.07.021,0.0,0.0,7.71,1.63,7.71,1.63,Control,GM,In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study.,0.6076,0.0858,0.2432,0.0821,14.0,5.0,9.0,27.71,5.88
mI,2018_egerton_23,7,10.1038/s41380-018-0082-9,0.76,0.1,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
mI,2018_egerton_23,8,10.1038/s41380-018-0082-9,0.69,0.1,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
mI,2018_egerton_23,9,10.1038/s41380-018-0082-9,0.72,0.03,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
mI,2018_egerton_23,10,10.1038/s41380-018-0082-9,0.56,0.1,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
mI,2018_egerton_23,11,10.1038/s41380-018-0082-9,0.7,0.09,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
mI,2018_egerton_23,12,10.1038/s41380-018-0082-9,0.67,0.1,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
mI,2018_egerton_23,1,10.1038/s41380-018-0082-9,0.77,0.14,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
mI,2018_egerton_23,2,10.1038/s41380-018-0082-9,0.72,0.06,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
mI,2018_egerton_23,3,10.1038/s41380-018-0082-9,0.72,0.07,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
mI,2018_egerton_23,4,10.1038/s41380-018-0082-9,0.58,0.1,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
mI,2018_egerton_23,5,10.1038/s41380-018-0082-9,0.64,0.1,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
mI,2018_egerton_23,6,10.1038/s41380-018-0082-9,0.65,0.08,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
mI,2018_ford_10,4,10.3390/nu10121860,0.0,0.0,4.73,0.15,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7181000000000001,0.038,0.2357,0.0458,14.0,10.0,4.0,43.0,0
mI,2018_ford_10,2,10.3390/nu10121860,0.0,0.0,4.53,0.15,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7239,0.0435,0.23550000000000001,0.0489,17.0,11.0,6.0,43.0,0
mI,2018_plitman_273,2,10.1016/j.pscychresns.2018.01.004,0.0,0.0,5.6,1.82,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
mI,2018_plitman_273,5,10.1016/j.pscychresns.2018.01.004,0.0,0.0,6.46,1.82,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
mI,2018_plitman_273,6,10.1016/j.pscychresns.2018.01.004,0.0,0.0,6.49,1.26,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
mI,2018_shakory_43,1,10.1038/s41386-018-0163-0,0.0,0.0,7.3,1.01,0.0,0.0,Control,GM,Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.,0.6,0.11,0.35,0.091,31.0,18.0,13.0,22.2,3.1
mI,2018_sheth_276,3,10.1016/j.pscychresns.2018.04.004,0.0,0.0,1.38,0.1,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.7021999999999999,0.03,0.2978,0.03,24.0,5.0,19.0,36.2,9.7
mI,2018_sheth_276,4,10.1016/j.pscychresns.2018.04.004,0.0,0.0,1.28,0.03,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.6139,0.043,0.3861,0.043,24.0,5.0,19.0,36.2,9.7
mI,2018_soeiro-de-souza_241,1,10.1016/j.jad.2018.08.039,0.0,0.0,8.183,1.09,8.183,1.09,Control,GM,Lithium-associated anterior cingulate neurometabolic profile in euthymic Bipolar I disorder: A (1)H-MRS study.,0.6273,0.04,0.1762,0.04,79.0,85.0,44.0,28.4,8.1
mI,2018_veeramuthu_25,3,10.1016/j.acra.2018.01.005,0.894,0.129,1.576,0.271,0.0,0.0,Control,WM,Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI): An In Vivo Proton Magnetic Resonance Spectroscopy (1H-MRS) Study.,0.0,0.0,0.0,0.0,13.0,5.0,8.0,27.15,4.88
mI,2018_white_43,2,10.1038/s41386-018-0027-7,0.0,0.0,5.12,0.55,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
mI,2018_white_43,3,10.1038/s41386-018-0027-7,0.0,0.0,4.86,0.58,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
mI,2018_white_43,1,10.1038/s41386-018-0027-7,0.0,0.0,4.8,0.5,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
mI,2019_bossong_76,1,10.1001/jamapsychiatry.2018.3252,0.0,0.0,6.19,1.51,6.19,1.51,Control,GM,Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis.,0.64,0.07,0.33,0.08,30.0,16.0,14.0,24.7,3.8
mI,2019_bustillo_246,1,10.1016/j.jad.2018.12.064,0.0,0.0,13.0,1.6,13.0,1.6,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
mI,2019_bustillo_246,2,10.1016/j.jad.2018.12.064,0.0,0.0,8.4,1.6,8.4,1.6,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
mI,2019_bustillo_246,3,10.1016/j.jad.2018.12.064,0.0,0.0,14.4,2.2,14.4,2.2,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
mI,2019_bustillo_246,4,10.1016/j.jad.2018.12.064,0.0,0.0,10.0,1.9,10.0,1.9,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
mI,2019_davitz_50,9,10.1002/jmri.26718,0.0,0.0,5.6,1.2,5.6,1.2,Control,WM,Quantitative multivoxel proton MR spectroscopy for the identification of white matter abnormalities in mild traumatic brain injury: Comparison between regional and global analysis.,0.0,0.0,0.0,0.0,12.0,4.0,8.0,34.0,0
mI,2019_davitz_50,10,10.1002/jmri.26718,0.0,0.0,5.1,1.1,5.1,1.1,Control,WM,Quantitative multivoxel proton MR spectroscopy for the identification of white matter abnormalities in mild traumatic brain injury: Comparison between regional and global analysis.,0.0,0.0,0.0,0.0,12.0,4.0,8.0,34.0,0
mI,2019_monnig_54,1,10.1093/alcalc/agz062,0.794,0.116,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolites on the Descending Limb of Acute Alcohol: A Preliminary 1H MRS Study.,0.0,0.0,0.0,0.0,13.0,8.0,5.0,26.4,2.8
mI,2019_pflugrad_14,12,10.1371/journal.pone.0221626,0.0,0.0,3.08,0.63,0.0,0.0,Control,WM,Cerebral metabolite alterations in patients with posttransplant encephalopathy after liver transplantation,0.0,0.0,0.0,0.0,20.0,14.0,6.0,47.8,10.8
mI,2019_reid_45,1,10.1093/schbul/sbx190,0.0,0.0,5.03,0.5,0.0,0.0,Control,GM,7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.,0.7140000000000001,0.078,0.254,0.077,21.0,5.0,16.0,23.5,4.5
mI,2019_schmitz_49,1,10.1111/apt.15256,0.0,0.0,3.181,0.425,0.0,0.0,Control,WM,Brain metabolic alterations in patients with long-term calcineurin inhibitor therapy after liver transplantation.,0.0,0.0,0.0,0.0,32.0,17.0,15.0,58.6,7.7
mI,2019_sheth_248,3,10.1016/j.jad.2019.01.037,0.74,0.11,1.59,4.2e-05,0.0,0.0,Control,GM,Reduced gamma-amino butyric acid (GABA) and glutamine in the anterior cingulate cortex (ACC) of veterans exposed to trauma.,0.703,0.03,0.297,0.037000000000000005,28.0,4.0,24.0,35.4,8.6
mI,2019_wiegers_62,1,10.1007/s00125-019-4862-9,0.0,0.0,5.51,0.79,5.51,0.79,Control,WM,Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status.,0.265,0.042,0.713,0.047,13.0,7.0,6.0,25.5,5.5
mI,2020_blest-hopley_25,2,10.1111/adb.12827,0.0,0.0,6.761,0.99,0.0,0.0,Control,GM,Adolescent-onset heavy cannabis use associated with significantly reduced glial but not neuronal markers and glutamate levels in the hippocampus.,0.6365,0.058,0.3099,0.098,21.0,12.0,9.0,24.24,4.11
mI,2020_kumar_25,1,10.1038/s41380-018-0104-7,0.0,0.0,3.68,0.46,3.68,0.46,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.743,0.067,0.111,0.064,45.0,16.0,29.0,27.89,7.54
mI,2020_kumar_25,2,10.1038/s41380-018-0104-7,0.0,0.0,3.33,0.39,3.33,0.39,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.637,0.046,0.285,0.051,45.0,16.0,29.0,27.89,7.54
mI,2020_kumar_25,3,10.1038/s41380-018-0104-7,0.0,0.0,3.87,0.53,3.87,0.53,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.6759999999999999,0.051,0.226,0.085,45.0,16.0,29.0,27.89,7.54
mI,2020_lind_40,1,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,5.67,0.41,5.67,0.41,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.64669,0.0,0.23431000000000002,0.0,20.0,10.0,10.0,22.6,2.37
mI,2020_lind_40,4,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,5.16,0.56,5.16,0.56,Control,WM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.29254,0.0,0.66486,0.0,20.0,10.0,10.0,22.6,2.37
mI,2020_lind_40,10,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,4.39,0.7,4.39,0.7,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.6731999999999999,0.0,0.3268,0.0,20.0,10.0,10.0,22.6,2.37
mI,2020_poletti_11,2,10.3389/fpsyt.2020.590095,0.0,0.0,4.29,0.86,0.0,0.0,Control,GM,Proinflammatory Cytokines Predict Brain Metabolite Concentrations in the Anterior Cingulate Cortex of Patients With Bipolar Disorder,0.7745000000000001,0.0795,0.8101999999999999,0.10279999999999999,49.0,21.0,28.0,33.7,11.14
mI,2020_sheth_123,2,10.1152/jn.00765.2019,0.0,0.0,1.31,0.08,0.0,0.0,Control,GM,Increased myoinositol in the anterior cingulate cortex of veterans with a history of traumatic brain injury: a proton magnetic resonance spectroscopy study.,0.6990000000000001,0.028999999999999998,0.3,0.028999999999999998,26.0,0.0,0.0,34.3,9.2
mI,2020_tran_30,1,10.1111/jon.12728,0.75,0.1,0.0,0.0,0.0,0.0,Control,GM,Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis.,0.0,0.0,0.0,0.0,16.0,6.0,10.0,57.8,11.7
mI,2020_tran_30,2,10.1111/jon.12728,0.81,0.1,0.0,0.0,0.0,0.0,Control,WM,Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis.,0.0,0.0,0.0,0.0,16.0,6.0,10.0,57.8,11.7
mI,2021_bednarik_15,1,10.3389/fnins.2021.609485,0.0,0.0,6.34,0.1,6.34,0.1,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7240000000000001,0.0178,0.18600000000000003,0.031,12.0,0.0,12.0,26.0,5
mI,2021_bednarik_15,2,10.3389/fnins.2021.609485,0.0,0.0,6.21,0.12,6.21,0.12,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7340000000000001,0.018000000000000002,0.17800000000000002,0.032,12.0,0.0,12.0,26.0,5
mI,2021_gajdosik_34,1,10.1002/nbm.4538,0.0,0.0,5.0,2.0,5.0,2.0,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,2.0,1.0,32.5,10.2
mI,2021_gajdosik_34,2,10.1002/nbm.4538,0.0,0.0,5.8,0.5,5.8,0.5,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,1.0,2.0,32.5,10.2
mI,2021_gramegna_8,6,10.1002/acn3.51329,0.73,0.07,0.0,0.0,0.0,0.0,Control,WM,Brain MRS correlates with mitochondrial dysfunction biomarkers in MELAS-associated mtDNA mutations,0.0,0.0,0.0,0.0,39.0,0.0,0.0,42.2,0
NAA,2017_bustillo_43,1,10.1093/schbul/sbw122,0.0,0.0,5.3,0.8,5.3,0.8,Control,WM,Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample.,0.37,0.17,0.63,0.0,97.0,69.0,28.0,37.1,12.3
NAA,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,10.82,0.6185,10.82,0.6185,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
NAA,2017_suri_152,1,10.1016/j.neuroimage.2017.03.031,1.44,0.078,0.0,0.0,0.0,0.0,Control,GM,Effect of age and the APOE gene on metabolite concentrations in the posterior cingulate cortex.,0.6,0.03,0.23,0.03,30.0,13.0,17.0,23.87,4.95
NAA,2018_burger_185,17,10.1016/j.drugalcdep.2017.11.029,1.315,0.102,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
NAA,2018_burger_185,18,10.1016/j.drugalcdep.2017.11.029,1.423,0.177,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
NAA,2018_caravaggio_28,1,10.1016/j.euroneuro.2017.12.002,0.0,0.0,8.89,1.26,0.0,0.0,Healthy,WM,Reduced insulin sensitivity may be related to less striatal glutamate: An (1)H-MRS study in healthy non-obese humans.,0.2921,0.0391,0.6297999999999999,0.0621,17.0,9.0,8.0,28.35,9.53
NAA,2018_caravaggio_28,2,10.1016/j.euroneuro.2017.12.002,0.0,0.0,8.22,1.47,0.0,0.0,Healthy,WM,Reduced insulin sensitivity may be related to less striatal glutamate: An (1)H-MRS study in healthy non-obese humans.,0.2465,0.028399999999999998,0.6658,0.06709999999999999,17.0,9.0,8.0,28.35,9.53
NAA,2018_chiu_193,4,10.1016/j.schres.2017.07.021,0.0,0.0,9.51,1.76,9.51,1.76,Control,GM,In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study.,0.6076,0.0858,0.2432,0.0821,14.0,5.0,9.0,27.71,5.88
NAA,2018_huber_225,3,10.1016/j.jad.2017.07.052,0.0,0.0,9.32,0.45,0.0,0.0,Control,GM,Relationship of executive functioning deficits to N-acetyl aspartate (NAA) and gamma-aminobutyric acid (GABA) in youth with bipolar disorder.,0.7020000000000001,0.031,0.0,0.0,10.0,5.0,5.0,19.0,1.56
NAA,2018_huber_225,4,10.1016/j.jad.2017.07.052,0.0,0.0,10.01,0.62,0.0,0.0,Control,GM,Relationship of executive functioning deficits to N-acetyl aspartate (NAA) and gamma-aminobutyric acid (GABA) in youth with bipolar disorder.,0.642,0.047,0.0,0.0,10.0,5.0,5.0,19.0,1.56
NAA,2018_shakory_43,1,10.1038/s41386-018-0163-0,0.0,0.0,8.72,0.78,0.0,0.0,Control,GM,Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.,0.6,0.11,0.35,0.091,31.0,18.0,13.0,22.2,3.1
NAA,2018_sheth_276,3,10.1016/j.pscychresns.2018.04.004,0.0,0.0,2.6,0.17,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.7021999999999999,0.03,0.2978,0.03,24.0,5.0,19.0,36.2,9.7
NAA,2018_sheth_276,4,10.1016/j.pscychresns.2018.04.004,0.0,0.0,2.83,0.06,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.6139,0.043,0.3861,0.043,24.0,5.0,19.0,36.2,9.7
NAA,2018_soeiro-de-souza_241,1,10.1016/j.jad.2018.08.039,0.0,0.0,15.183,1.462,15.183,1.462,Control,GM,Lithium-associated anterior cingulate neurometabolic profile in euthymic Bipolar I disorder: A (1)H-MRS study.,0.6273,0.04,0.1762,0.04,79.0,85.0,44.0,28.4,8.1
NAA,2018_veeramuthu_25,3,10.1016/j.acra.2018.01.005,1.72,0.125,3.019,0.284,0.0,0.0,Control,WM,Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI): An In Vivo Proton Magnetic Resonance Spectroscopy (1H-MRS) Study.,0.0,0.0,0.0,0.0,13.0,5.0,8.0,27.15,4.88
NAA,2019_bossong_76,1,10.1001/jamapsychiatry.2018.3252,0.0,0.0,9.34,1.43,9.34,1.43,Control,GM,Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis.,0.64,0.07,0.33,0.08,30.0,16.0,14.0,24.7,3.8
NAA,2019_davitz_50,9,10.1002/jmri.26718,0.0,0.0,8.4,1.5,8.4,1.5,Control,WM,Quantitative multivoxel proton MR spectroscopy for the identification of white matter abnormalities in mild traumatic brain injury: Comparison between regional and global analysis.,0.0,0.0,0.0,0.0,12.0,4.0,8.0,34.0,0
NAA,2019_davitz_50,10,10.1002/jmri.26718,0.0,0.0,7.7,1.3,7.7,1.3,Control,WM,Quantitative multivoxel proton MR spectroscopy for the identification of white matter abnormalities in mild traumatic brain injury: Comparison between regional and global analysis.,0.0,0.0,0.0,0.0,12.0,4.0,8.0,34.0,0
NAA,2019_khomenko_49,1,10.1007/s11055-019-00858-1,1.96,0.21,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
NAA,2019_khomenko_49,2,10.1007/s11055-019-00858-1,2.05,0.19,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
NAA,2019_khomenko_49,3,10.1007/s11055-019-00858-1,1.98,0.18,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
NAA,2019_khomenko_49,4,10.1007/s11055-019-00858-1,2.02,0.18,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
NAA,2019_khomenko_49,5,10.1007/s11055-019-00858-1,2.16,0.2,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
NAA,2019_khomenko_49,6,10.1007/s11055-019-00858-1,2.1,0.18,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
NAA,2019_khomenko_49,7,10.1007/s11055-019-00858-1,1.58,0.11,0.0,0.0,0.0,0.0,Control,GM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
NAA,2019_khomenko_49,8,10.1007/s11055-019-00858-1,1.56,0.14,0.0,0.0,0.0,0.0,Control,GM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
NAA,2019_khomenko_49,9,10.1007/s11055-019-00858-1,1.62,0.11,0.0,0.0,0.0,0.0,Control,GM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
NAA,2019_pflugrad_14,12,10.1371/journal.pone.0221626,0.0,0.0,5.6,0.0,0.0,0.0,Control,WM,Cerebral metabolite alterations in patients with posttransplant encephalopathy after liver transplantation,0.0,0.0,0.0,0.0,20.0,14.0,6.0,47.8,10.8
NAA,2019_reid_45,1,10.1093/schbul/sbx190,0.0,0.0,6.82,0.53,0.0,0.0,Control,GM,7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.,0.7140000000000001,0.078,0.254,0.077,21.0,5.0,16.0,23.5,4.5
NAA,2019_schmitz_49,1,10.1111/apt.15256,0.0,0.0,6.415,0.493,0.0,0.0,Control,WM,Brain metabolic alterations in patients with long-term calcineurin inhibitor therapy after liver transplantation.,0.0,0.0,0.0,0.0,32.0,17.0,15.0,58.6,7.7
NAA,2019_sheth_248,3,10.1016/j.jad.2019.01.037,1.36,0.16,0.0,0.0,0.0,0.0,Control,GM,Reduced gamma-amino butyric acid (GABA) and glutamine in the anterior cingulate cortex (ACC) of veterans exposed to trauma.,0.703,0.03,0.297,0.037000000000000005,28.0,4.0,24.0,35.4,8.6
NAA,2019_wang_76,6,10.1001/jamapsychiatry.2018.3637,0.0,0.0,7.8,1.2,0.0,0.0,Control,GM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.725,0.12,0.17,0.09,91.0,49.0,42.0,23.3,3.9
NAA,2019_wang_76,7,10.1001/jamapsychiatry.2018.3637,0.0,0.0,7.7,0.8,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.1,0.12,0.88,0.14,91.0,49.0,42.0,23.3,3.9
NAA,2019_wang_76,9,10.1001/jamapsychiatry.2018.3637,0.0,0.0,7.5,1.0,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.27,0.15,0.75,0.11,91.0,49.0,42.0,23.3,3.9
NAA,2019_wang_76,10,10.1001/jamapsychiatry.2018.3637,0.0,0.0,7.5,1.0,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.3,0.18,0.66,0.2,91.0,49.0,42.0,23.3,3.9
NAA,2020_kumar_25,1,10.1038/s41380-018-0104-7,0.0,0.0,5.15,0.62,5.15,0.62,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.743,0.067,0.111,0.064,45.0,16.0,29.0,27.89,7.54
NAA,2020_kumar_25,2,10.1038/s41380-018-0104-7,0.0,0.0,6.13,0.46,6.13,0.46,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.637,0.046,0.285,0.051,45.0,16.0,29.0,27.89,7.54
NAA,2020_kumar_25,3,10.1038/s41380-018-0104-7,0.0,0.0,5.16,0.51,5.16,0.51,Control,GM,Glutathione and glutamate in schizophrenia: a 7T MRS study.,0.6759999999999999,0.051,0.226,0.085,45.0,16.0,29.0,27.89,7.54
NAA,2020_lind_40,4,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,10.16,0.69,10.16,0.69,Control,WM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.29254,0.0,0.66486,0.0,20.0,10.0,10.0,22.6,2.37
NAA,2020_poletti_11,2,10.3389/fpsyt.2020.590095,0.0,0.0,7.14,0.54,0.0,0.0,Control,GM,Proinflammatory Cytokines Predict Brain Metabolite Concentrations in the Anterior Cingulate Cortex of Patients With Bipolar Disorder,0.7745000000000001,0.0795,0.8101999999999999,0.10279999999999999,49.0,21.0,28.0,33.7,11.14
NAA,2020_sheth_123,2,10.1152/jn.00765.2019,0.0,0.0,2.72,0.13,0.0,0.0,Control,GM,Increased myoinositol in the anterior cingulate cortex of veterans with a history of traumatic brain injury: a proton magnetic resonance spectroscopy study.,0.6990000000000001,0.028999999999999998,0.3,0.028999999999999998,26.0,0.0,0.0,34.3,9.2
NAA,2021_bednarik_15,1,10.3389/fnins.2021.609485,0.0,0.0,11.8,0.3,11.8,0.3,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7240000000000001,0.0178,0.18600000000000003,0.031,12.0,0.0,12.0,26.0,5
NAA,2021_bednarik_15,2,10.3389/fnins.2021.609485,0.0,0.0,11.6,0.3,11.6,0.3,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7340000000000001,0.018000000000000002,0.17800000000000002,0.032,12.0,0.0,12.0,26.0,5
NAA,2021_gajdosik_34,1,10.1002/nbm.4538,0.0,0.0,5.9,0.5,5.9,0.5,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,2.0,1.0,32.5,10.2
NAA,2021_gajdosik_34,2,10.1002/nbm.4538,0.0,0.0,5.9,0.3,5.9,0.3,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,1.0,2.0,32.5,10.2
NAA,2021_gramegna_8,6,10.1002/acn3.51329,1.39,0.11,0.0,0.0,0.0,0.0,Control,WM,Brain MRS correlates with mitochondrial dysfunction biomarkers in MELAS-associated mtDNA mutations,0.0,0.0,0.0,0.0,39.0,0.0,0.0,42.2,0
NAA,2021_gramegna_8,6,10.1002/acn3.51329,0.0,0.0,0.0,0.0,0.0,0.0,Control,WM,Brain MRS correlates with mitochondrial dysfunction biomarkers in MELAS-associated mtDNA mutations,0.0,0.0,0.0,0.0,39.0,0.0,0.0,42.2,0
NAAG,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,1.17,0.3711,1.17,0.3711,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
NAAG,2019_reid_45,1,10.1093/schbul/sbx190,0.0,0.0,0.46,0.1,0.0,0.0,Control,GM,7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.,0.7140000000000001,0.078,0.254,0.077,21.0,5.0,16.0,23.5,4.5
NAAG,2019_wang_76,6,10.1001/jamapsychiatry.2018.3637,0.0,0.0,0.8,0.2,0.0,0.0,Control,GM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.725,0.12,0.17,0.09,91.0,49.0,42.0,23.3,3.9
NAAG,2019_wang_76,7,10.1001/jamapsychiatry.2018.3637,0.0,0.0,2.2,0.5,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.1,0.12,0.88,0.14,91.0,49.0,42.0,23.3,3.9
NAAG,2019_wang_76,9,10.1001/jamapsychiatry.2018.3637,0.0,0.0,0.95,0.5,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.27,0.15,0.75,0.11,91.0,49.0,42.0,23.3,3.9
NAAG,2019_wang_76,10,10.1001/jamapsychiatry.2018.3637,0.0,0.0,1.4,0.8,0.0,0.0,Control,WM,Assessing Brain Metabolism With 7-T Proton Magnetic Resonance Spectroscopy in Patients With First-Episode Psychosis.,0.3,0.18,0.66,0.2,91.0,49.0,42.0,23.3,3.9
PCr,2019_reid_45,1,10.1093/schbul/sbx190,0.0,0.0,3.36,0.35,0.0,0.0,Control,GM,7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.,0.7140000000000001,0.078,0.254,0.077,21.0,5.0,16.0,23.5,4.5
PE,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,2.12,0.2062,2.12,0.2062,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
sI,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,0.26,0.2062,0.26,0.2062,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
sI,2019_wiegers_62,1,10.1007/s00125-019-4862-9,0.0,0.0,0.57,0.17,0.57,0.17,Control,WM,Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status.,0.265,0.042,0.713,0.047,13.0,7.0,6.0,25.5,5.5
sI,2021_gajdosik_34,1,10.1002/nbm.4538,0.0,0.0,0.6,0.2,0.6,0.2,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,2.0,1.0,32.5,10.2
sI,2021_gajdosik_34,2,10.1002/nbm.4538,0.0,0.0,0.4,0.4,0.4,0.4,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,1.0,2.0,32.5,10.2
Tau,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,1.86,0.2474,1.86,0.2474,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
Tau,2019_reid_45,1,10.1093/schbul/sbx190,0.0,0.0,1.48,0.12,0.0,0.0,Control,GM,7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.,0.7140000000000001,0.078,0.254,0.077,21.0,5.0,16.0,23.5,4.5
Tau,2019_strasser_29,1,10.1016/j.euroneuro.2018.12.015,0.0,0.0,1.14,0.33,1.14,0.33,Healthy,GM,Nucleus accumbens neurochemistry in human anxiety: A 7T H-1-MRS study,0.85,0.04,0.12,0.05,38.0,0.0,38.0,25.0,20-30
Tau,2019_wiegers_62,1,10.1007/s00125-019-4862-9,0.0,0.0,1.74,0.5,1.74,0.5,Control,WM,Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status.,0.265,0.042,0.713,0.047,13.0,7.0,6.0,25.5,5.5
Tau,2021_bednarik_15,1,10.3389/fnins.2021.609485,0.0,0.0,2.1,0.04,2.1,0.04,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7240000000000001,0.0178,0.18600000000000003,0.031,12.0,0.0,12.0,26.0,5
Tau,2021_bednarik_15,2,10.3389/fnins.2021.609485,0.0,0.0,1.98,0.1,1.98,0.1,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7340000000000001,0.018000000000000002,0.17800000000000002,0.032,12.0,0.0,12.0,26.0,5
Cr,2017_bustillo_43,1,10.1093/schbul/sbw122,0.0,0.0,2.85,0.4,2.85,0.4,Control,WM,Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample.,0.37,0.17,0.63,0.0,97.0,69.0,28.0,37.1,12.3
Cr,2018_plitman_273,2,10.1016/j.pscychresns.2018.01.004,0.0,0.0,4.1,0.525,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
Cr,2018_plitman_273,5,10.1016/j.pscychresns.2018.01.004,0.0,0.0,4.42,0.795,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
Cr,2018_plitman_273,6,10.1016/j.pscychresns.2018.01.004,0.0,0.0,4.355,0.58,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
Cr,2018_tiwari_80,2,10.1002/mrm.27142,0.0,0.0,3.025,0.215,3.025,0.215,Healthy,WM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.16,0.05,0.81,0.08,6.0,3.0,3.0,27.0,5
Cr,2018_tiwari_80,3,10.1002/mrm.27142,0.0,0.0,4.15,0.33,4.15,0.33,Healthy,WM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.0,0.0,0.0,0.0,6.0,3.0,3.0,27.0,5
Cr,2018_veeramuthu_25,3,10.1016/j.acra.2018.01.005,0.0,0.0,0.883,0.1125,0.0,0.0,Control,WM,Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI): An In Vivo Proton Magnetic Resonance Spectroscopy (1H-MRS) Study.,0.0,0.0,0.0,0.0,13.0,5.0,8.0,27.15,4.88
Cr,2019_bustillo_246,2,10.1016/j.jad.2018.12.064,0.0,0.0,5.4,0.5,5.4,0.5,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
Cr,2019_bustillo_246,4,10.1016/j.jad.2018.12.064,0.0,0.0,5.85,0.75,5.85,0.75,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
Cr,2019_ferland_237,1,10.1007/s00221-019-05691-z,0.0,0.0,8.6295,0.8235,8.6295,0.8235,Healthy,WM,Longitudinal assessment of (1)H-MRS (GABA and Glx) and TMS measures of cortical inhibition and facilitation in the sensorimotor cortex.,0.22399999999999998,0.04,0.743,0.048,10.0,5.0,5.0,26.0,4
Cr,2019_ferland_237,2,10.1007/s00221-019-05691-z,0.0,0.0,8.8475,0.4285,8.8475,0.4285,Healthy,WM,Longitudinal assessment of (1)H-MRS (GABA and Glx) and TMS measures of cortical inhibition and facilitation in the sensorimotor cortex.,0.22399999999999998,0.052000000000000005,0.742,0.057999999999999996,10.0,5.0,5.0,26.0,4
Cr,2019_schmitz_49,1,10.1111/apt.15256,0.0,0.0,2.1525,0.1905,0.0,0.0,Control,WM,Brain metabolic alterations in patients with long-term calcineurin inhibitor therapy after liver transplantation.,0.0,0.0,0.0,0.0,32.0,17.0,15.0,58.6,7.7
Cr,2019_wiegers_62,1,10.1007/s00125-019-4862-9,0.0,0.0,3.47,0.205,3.47,0.205,Control,WM,Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status.,0.265,0.042,0.713,0.047,13.0,7.0,6.0,25.5,5.5
Cr,2020_lind_40,4,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,3.395,0.25,3.395,0.25,Control,WM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.29254,0.0,0.66486,0.0,20.0,10.0,10.0,22.6,2.37
Cr,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,4.445,0.2886,4.445,0.2886,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
Cr,2018_ford_10,4,10.3390/nu10121860,0.0,0.0,3.98,0.065,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7181000000000001,0.038,0.2357,0.0458,14.0,10.0,4.0,43.0,0
Cr,2018_ford_10,2,10.3390/nu10121860,0.0,0.0,3.87,0.075,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7239,0.0435,0.23550000000000001,0.0489,17.0,11.0,6.0,43.0,0
Cr,2018_shakory_43,1,10.1038/s41386-018-0163-0,0.0,0.0,3.585,0.35,0.0,0.0,Control,GM,Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.,0.6,0.11,0.35,0.091,31.0,18.0,13.0,22.2,3.1
Cr,2018_sheth_276,3,10.1016/j.pscychresns.2018.04.004,0.0,0.0,1.06,0.065,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.7021999999999999,0.03,0.2978,0.03,24.0,5.0,19.0,36.2,9.7
Cr,2018_sheth_276,4,10.1016/j.pscychresns.2018.04.004,0.0,0.0,0.94,0.03,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.6139,0.043,0.3861,0.043,24.0,5.0,19.0,36.2,9.7
Cr,2018_tiwari_80,1,10.1002/mrm.27142,0.0,0.0,4.0,0.285,4.0,0.285,Healthy,GM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.61,0.03,0.23,0.02,6.0,3.0,3.0,27.0,5
Cr,2018_tiwari_80,5,10.1002/mrm.27142,0.0,0.0,4.04,0.24,4.04,0.24,Healthy,GM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.0,0.0,0.0,0.0,6.0,3.0,3.0,27.0,5
Cr,2018_tiwari_80,6,10.1002/mrm.27142,0.0,0.0,3.14,0.1,3.14,0.1,Healthy,GM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.0,0.0,0.0,0.0,6.0,3.0,3.0,27.0,5
Cr,2018_white_43,2,10.1038/s41386-018-0027-7,0.0,0.0,3.28,0.32,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
Cr,2018_white_43,3,10.1038/s41386-018-0027-7,0.0,0.0,3.17,0.265,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
Cr,2018_white_43,1,10.1038/s41386-018-0027-7,0.0,0.0,3.14,0.27,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
Cr,2019_bustillo_246,1,10.1016/j.jad.2018.12.064,0.0,0.0,7.85,0.75,7.85,0.75,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
Cr,2019_bustillo_246,3,10.1016/j.jad.2018.12.064,0.0,0.0,8.4,0.9,8.4,0.9,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
Cr,2019_mikkelsen_191,1,10.1016/j.neuroimage.2019.02.059,0.0,0.0,7.89,0.68,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.6,0.05,0.26,0.04,12.0,7.0,5.0,23.92,4.81
Cr,2019_mikkelsen_191,3,10.1016/j.neuroimage.2019.02.059,0.0,0.0,6.885,0.495,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.6,0.03,0.29,0.02,7.0,2.0,5.0,23.43,5.47
Cr,2019_mikkelsen_191,4,10.1016/j.neuroimage.2019.02.059,0.0,0.0,7.14,0.36,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.6,0.03,0.28,0.02,12.0,6.0,6.0,25.58,4.48
Cr,2019_mikkelsen_191,5,10.1016/j.neuroimage.2019.02.059,0.0,0.0,6.955,0.27,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.65,0.05,0.26,0.01,12.0,5.0,7.0,25.5,3.73
Cr,2019_mikkelsen_191,10,10.1016/j.neuroimage.2019.02.059,0.0,0.0,7.745,0.475,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.6,0.03,0.27,0.04,12.0,6.0,6.0,25.08,3.23
Cr,2019_mikkelsen_191,14,10.1016/j.neuroimage.2019.02.059,0.0,0.0,7.635,0.535,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.63,0.03,0.27,0.02,8.0,3.0,5.0,23.13,2.36
Cr,2019_mikkelsen_191,16,10.1016/j.neuroimage.2019.02.059,0.0,0.0,8.01,0.255,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.63,0.03,0.27,0.03,12.0,6.0,6.0,23.58,3.73
Cr,2019_mikkelsen_191,17,10.1016/j.neuroimage.2019.02.059,0.0,0.0,9.345,0.345,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.61,0.04,0.28,0.03,12.0,5.0,7.0,23.25,1.96
Cr,2019_mikkelsen_191,23,10.1016/j.neuroimage.2019.02.059,0.0,0.0,9.51,0.355,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.61,0.03,0.29,0.02,12.0,6.0,6.0,27.67,2.77
Cr,2019_reid_45,1,10.1093/schbul/sbx190,0.0,0.0,2.87,0.19,0.0,0.0,Control,GM,7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.,0.7140000000000001,0.078,0.254,0.077,21.0,5.0,16.0,23.5,4.5
Cr,2019_sheth_248,3,10.1016/j.jad.2019.01.037,0.0,0.0,1.095,0.0,0.0,0.0,Control,GM,Reduced gamma-amino butyric acid (GABA) and glutamine in the anterior cingulate cortex (ACC) of veterans exposed to trauma.,0.703,0.03,0.297,0.037000000000000005,28.0,4.0,24.0,35.4,8.6
Cr,2020_lind_40,1,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,3.48,0.17,3.48,0.17,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.64669,0.0,0.23431000000000002,0.0,20.0,10.0,10.0,22.6,2.37
Cr,2020_lind_40,10,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,3.065,0.335,3.065,0.335,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.6731999999999999,0.0,0.3268,0.0,20.0,10.0,10.0,22.6,2.37
Cr,2020_sheth_123,2,10.1152/jn.00765.2019,0.0,0.0,1.02,0.055,0.0,0.0,Control,GM,Increased myoinositol in the anterior cingulate cortex of veterans with a history of traumatic brain injury: a proton magnetic resonance spectroscopy study.,0.6990000000000001,0.028999999999999998,0.3,0.028999999999999998,26.0,0.0,0.0,34.3,9.2
Cr,2021_bednarik_15,1,10.3389/fnins.2021.609485,0.0,0.0,4.1,0.1,4.1,0.1,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7240000000000001,0.0178,0.18600000000000003,0.031,12.0,0.0,12.0,26.0,5
Cr,2021_bednarik_15,2,10.3389/fnins.2021.609485,0.0,0.0,4.05,0.1,4.05,0.1,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7340000000000001,0.018000000000000002,0.17800000000000002,0.032,12.0,0.0,12.0,26.0,5
PCr,2017_bustillo_43,1,10.1093/schbul/sbw122,0.0,0.0,1.425,0.2,1.425,0.2,Control,WM,Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample.,0.37,0.17,0.63,0.0,97.0,69.0,28.0,37.1,12.3
PCr,2018_plitman_273,2,10.1016/j.pscychresns.2018.01.004,0.0,0.0,2.05,0.2625,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
PCr,2018_plitman_273,5,10.1016/j.pscychresns.2018.01.004,0.0,0.0,2.21,0.3975,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
PCr,2018_plitman_273,6,10.1016/j.pscychresns.2018.01.004,0.0,0.0,2.1775,0.29,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
PCr,2018_tiwari_80,2,10.1002/mrm.27142,0.0,0.0,1.5125,0.1075,1.5125,0.1075,Healthy,WM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.16,0.05,0.81,0.08,6.0,3.0,3.0,27.0,5
PCr,2018_tiwari_80,3,10.1002/mrm.27142,0.0,0.0,2.075,0.165,2.075,0.165,Healthy,WM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.0,0.0,0.0,0.0,6.0,3.0,3.0,27.0,5
PCr,2018_veeramuthu_25,3,10.1016/j.acra.2018.01.005,0.0,0.0,0.4415,0.05625,0.0,0.0,Control,WM,Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI): An In Vivo Proton Magnetic Resonance Spectroscopy (1H-MRS) Study.,0.0,0.0,0.0,0.0,13.0,5.0,8.0,27.15,4.88
PCr,2019_bustillo_246,2,10.1016/j.jad.2018.12.064,0.0,0.0,2.7,0.25,2.7,0.25,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
PCr,2019_bustillo_246,4,10.1016/j.jad.2018.12.064,0.0,0.0,2.925,0.375,2.925,0.375,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
PCr,2019_ferland_237,1,10.1007/s00221-019-05691-z,0.0,0.0,4.31475,0.41175,4.31475,0.41175,Healthy,WM,Longitudinal assessment of (1)H-MRS (GABA and Glx) and TMS measures of cortical inhibition and facilitation in the sensorimotor cortex.,0.22399999999999998,0.04,0.743,0.048,10.0,5.0,5.0,26.0,4
PCr,2019_ferland_237,2,10.1007/s00221-019-05691-z,0.0,0.0,4.42375,0.21425,4.42375,0.21425,Healthy,WM,Longitudinal assessment of (1)H-MRS (GABA and Glx) and TMS measures of cortical inhibition and facilitation in the sensorimotor cortex.,0.22399999999999998,0.052000000000000005,0.742,0.057999999999999996,10.0,5.0,5.0,26.0,4
PCr,2019_schmitz_49,1,10.1111/apt.15256,0.0,0.0,1.07625,0.09525,0.0,0.0,Control,WM,Brain metabolic alterations in patients with long-term calcineurin inhibitor therapy after liver transplantation.,0.0,0.0,0.0,0.0,32.0,17.0,15.0,58.6,7.7
PCr,2019_wiegers_62,1,10.1007/s00125-019-4862-9,0.0,0.0,1.735,0.1025,1.735,0.1025,Control,WM,Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status.,0.265,0.042,0.713,0.047,13.0,7.0,6.0,25.5,5.5
PCr,2020_lind_40,4,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,1.6975,0.125,1.6975,0.125,Control,WM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.29254,0.0,0.66486,0.0,20.0,10.0,10.0,22.6,2.37
PCr,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,2.2225,0.1443,2.2225,0.1443,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
PCr,2018_ford_10,4,10.3390/nu10121860,0.0,0.0,1.99,0.0325,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7181000000000001,0.038,0.2357,0.0458,14.0,10.0,4.0,43.0,0
PCr,2018_ford_10,2,10.3390/nu10121860,0.0,0.0,1.935,0.0375,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7239,0.0435,0.23550000000000001,0.0489,17.0,11.0,6.0,43.0,0
PCr,2018_shakory_43,1,10.1038/s41386-018-0163-0,0.0,0.0,1.7925,0.175,0.0,0.0,Control,GM,Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.,0.6,0.11,0.35,0.091,31.0,18.0,13.0,22.2,3.1
PCr,2018_sheth_276,3,10.1016/j.pscychresns.2018.04.004,0.0,0.0,0.53,0.0325,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.7021999999999999,0.03,0.2978,0.03,24.0,5.0,19.0,36.2,9.7
PCr,2018_sheth_276,4,10.1016/j.pscychresns.2018.04.004,0.0,0.0,0.47,0.015,0.0,0.0,Control,GM,Alterations in anterior cingulate cortex myoinositol and aggression in veterans with suicidal behavior: A proton magnetic resonance spectroscopy study.,0.6139,0.043,0.3861,0.043,24.0,5.0,19.0,36.2,9.7
PCr,2018_tiwari_80,1,10.1002/mrm.27142,0.0,0.0,2.0,0.1425,2.0,0.1425,Healthy,GM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.61,0.03,0.23,0.02,6.0,3.0,3.0,27.0,5
PCr,2018_tiwari_80,5,10.1002/mrm.27142,0.0,0.0,2.02,0.12,2.02,0.12,Healthy,GM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.0,0.0,0.0,0.0,6.0,3.0,3.0,27.0,5
PCr,2018_tiwari_80,6,10.1002/mrm.27142,0.0,0.0,1.57,0.05,1.57,0.05,Healthy,GM,Distinction of the GABA 2.29ppm resonance using triple refocusing at 3 T in vivo.,0.0,0.0,0.0,0.0,6.0,3.0,3.0,27.0,5
PCr,2018_white_43,2,10.1038/s41386-018-0027-7,0.0,0.0,1.64,0.16,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
PCr,2018_white_43,3,10.1038/s41386-018-0027-7,0.0,0.0,1.585,0.1325,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
PCr,2018_white_43,1,10.1038/s41386-018-0027-7,0.0,0.0,1.57,0.135,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
PCr,2019_bustillo_246,1,10.1016/j.jad.2018.12.064,0.0,0.0,3.925,0.375,3.925,0.375,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
PCr,2019_bustillo_246,3,10.1016/j.jad.2018.12.064,0.0,0.0,4.2,0.45,4.2,0.45,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
PCr,2019_mikkelsen_191,1,10.1016/j.neuroimage.2019.02.059,0.0,0.0,3.945,0.34,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.6,0.05,0.26,0.04,12.0,7.0,5.0,23.92,4.81
PCr,2019_mikkelsen_191,3,10.1016/j.neuroimage.2019.02.059,0.0,0.0,3.4425,0.2475,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.6,0.03,0.29,0.02,7.0,2.0,5.0,23.43,5.47
PCr,2019_mikkelsen_191,4,10.1016/j.neuroimage.2019.02.059,0.0,0.0,3.57,0.18,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.6,0.03,0.28,0.02,12.0,6.0,6.0,25.58,4.48
PCr,2019_mikkelsen_191,5,10.1016/j.neuroimage.2019.02.059,0.0,0.0,3.4775,0.135,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.65,0.05,0.26,0.01,12.0,5.0,7.0,25.5,3.73
PCr,2019_mikkelsen_191,10,10.1016/j.neuroimage.2019.02.059,0.0,0.0,3.8725,0.2375,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.6,0.03,0.27,0.04,12.0,6.0,6.0,25.08,3.23
PCr,2019_mikkelsen_191,14,10.1016/j.neuroimage.2019.02.059,0.0,0.0,3.8175,0.2675,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.63,0.03,0.27,0.02,8.0,3.0,5.0,23.13,2.36
PCr,2019_mikkelsen_191,16,10.1016/j.neuroimage.2019.02.059,0.0,0.0,4.005,0.1275,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.63,0.03,0.27,0.03,12.0,6.0,6.0,23.58,3.73
PCr,2019_mikkelsen_191,17,10.1016/j.neuroimage.2019.02.059,0.0,0.0,4.6725,0.1725,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.61,0.04,0.28,0.03,12.0,5.0,7.0,23.25,1.96
PCr,2019_mikkelsen_191,23,10.1016/j.neuroimage.2019.02.059,0.0,0.0,4.755,0.1775,0.0,0.0,Healthy,GM,Big GABA II: Water-referenced edited MR spectroscopy at 25 research sites.,0.61,0.03,0.29,0.02,12.0,6.0,6.0,27.67,2.77
PCr,2019_reid_45,1,10.1093/schbul/sbx190,0.0,0.0,1.435,0.095,0.0,0.0,Control,GM,7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.,0.7140000000000001,0.078,0.254,0.077,21.0,5.0,16.0,23.5,4.5
PCr,2019_sheth_248,3,10.1016/j.jad.2019.01.037,0.0,0.0,0.5475,0.0,0.0,0.0,Control,GM,Reduced gamma-amino butyric acid (GABA) and glutamine in the anterior cingulate cortex (ACC) of veterans exposed to trauma.,0.703,0.03,0.297,0.037000000000000005,28.0,4.0,24.0,35.4,8.6
PCr,2020_lind_40,1,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,1.74,0.085,1.74,0.085,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.64669,0.0,0.23431000000000002,0.0,20.0,10.0,10.0,22.6,2.37
PCr,2020_lind_40,10,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,1.5325,0.1675,1.5325,0.1675,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.6731999999999999,0.0,0.3268,0.0,20.0,10.0,10.0,22.6,2.37
PCr,2020_sheth_123,2,10.1152/jn.00765.2019,0.0,0.0,0.51,0.0275,0.0,0.0,Control,GM,Increased myoinositol in the anterior cingulate cortex of veterans with a history of traumatic brain injury: a proton magnetic resonance spectroscopy study.,0.6990000000000001,0.028999999999999998,0.3,0.028999999999999998,26.0,0.0,0.0,34.3,9.2
PCr,2021_bednarik_15,1,10.3389/fnins.2021.609485,0.0,0.0,2.05,0.05,2.05,0.05,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7240000000000001,0.0178,0.18600000000000003,0.031,12.0,0.0,12.0,26.0,5
PCr,2021_bednarik_15,2,10.3389/fnins.2021.609485,0.0,0.0,2.025,0.05,2.025,0.05,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7340000000000001,0.018000000000000002,0.17800000000000002,0.032,12.0,0.0,12.0,26.0,5
NAA,2018_burger_185,17,10.1016/j.drugalcdep.2017.11.029,1.417,0.167,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
NAA,2018_burger_185,18,10.1016/j.drugalcdep.2017.11.029,1.574,0.2,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
NAA,2018_egerton_23,10,10.1038/s41380-018-0082-9,1.65,0.18,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
NAA,2018_egerton_23,11,10.1038/s41380-018-0082-9,1.54,0.16,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
NAA,2018_egerton_23,12,10.1038/s41380-018-0082-9,1.53,0.1,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
NAA,2018_egerton_23,4,10.1038/s41380-018-0082-9,1.61,0.18,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
NAA,2018_egerton_23,5,10.1038/s41380-018-0082-9,1.54,0.19,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
NAA,2018_egerton_23,6,10.1038/s41380-018-0082-9,1.55,0.19,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
NAA,2018_plitman_273,2,10.1016/j.pscychresns.2018.01.004,0.0,0.0,8.0475,0.44999999999999996,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
NAA,2018_plitman_273,5,10.1016/j.pscychresns.2018.01.004,0.0,0.0,8.272499999999999,0.72,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
NAA,2018_plitman_273,6,10.1016/j.pscychresns.2018.01.004,0.0,0.0,8.040000000000001,0.5475,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
NAA,2018_veeramuthu_25,3,10.1016/j.acra.2018.01.005,2.059,0.11,2.715,0.264,0.0,0.0,Control,WM,Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI): An In Vivo Proton Magnetic Resonance Spectroscopy (1H-MRS) Study.,0.0,0.0,0.0,0.0,13.0,5.0,8.0,27.15,4.88
NAA,2019_bustillo_246,2,10.1016/j.jad.2018.12.064,0.0,0.0,13.049999999999999,0.8999999999999999,13.049999999999999,0.8999999999999999,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
NAA,2019_bustillo_246,4,10.1016/j.jad.2018.12.064,0.0,0.0,13.049999999999999,1.0499999999999998,13.049999999999999,1.0499999999999998,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
NAA,2019_ferland_237,1,10.1007/s00221-019-05691-z,0.0,0.0,16.701,0.3525,16.701,0.3525,Healthy,WM,Longitudinal assessment of (1)H-MRS (GABA and Glx) and TMS measures of cortical inhibition and facilitation in the sensorimotor cortex.,0.22399999999999998,0.04,0.743,0.048,10.0,5.0,5.0,26.0,4
NAA,2019_ferland_237,2,10.1007/s00221-019-05691-z,0.0,0.0,16.6275,0.5685,16.6275,0.5685,Healthy,WM,Longitudinal assessment of (1)H-MRS (GABA and Glx) and TMS measures of cortical inhibition and facilitation in the sensorimotor cortex.,0.22399999999999998,0.052000000000000005,0.742,0.057999999999999996,10.0,5.0,5.0,26.0,4
NAA,2019_monnig_54,1,10.1093/alcalc/agz062,1.61,0.113,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolites on the Descending Limb of Acute Alcohol: A Preliminary 1H MRS Study.,0.0,0.0,0.0,0.0,13.0,8.0,5.0,26.4,2.8
NAA,2019_wiegers_62,1,10.1007/s00125-019-4862-9,0.0,0.0,8.34,0.41250000000000003,8.34,0.41250000000000003,Control,WM,Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status.,0.265,0.042,0.713,0.047,13.0,7.0,6.0,25.5,5.5
NAA,2020_lind_40,4,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,8.3025,0.54,8.3025,0.54,Control,WM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.29254,0.0,0.66486,0.0,20.0,10.0,10.0,22.6,2.37
NAA,2020_tran_30,2,10.1111/jon.12728,1.82,0.23,0.0,0.0,0.0,0.0,Control,WM,Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis.,0.0,0.0,0.0,0.0,16.0,6.0,10.0,57.8,11.7
NAA,2018_egerton_23,7,10.1038/s41380-018-0082-9,1.26,0.15,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
NAA,2018_egerton_23,8,10.1038/s41380-018-0082-9,1.24,0.07,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
NAA,2018_egerton_23,9,10.1038/s41380-018-0082-9,1.17,0.04,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
NAA,2018_egerton_23,1,10.1038/s41380-018-0082-9,1.24,0.11,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
NAA,2018_egerton_23,2,10.1038/s41380-018-0082-9,1.23,0.09,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
NAA,2018_egerton_23,3,10.1038/s41380-018-0082-9,1.2,0.07,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
NAA,2018_evans_43,1,10.1038/s41386-018-0057-1,1.58,0.02,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
NAA,2018_evans_43,2,10.1038/s41386-018-0057-1,1.57,0.03,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
NAA,2018_evans_43,3,10.1038/s41386-018-0057-1,1.66,0.03,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
NAA,2018_ford_10,4,10.3390/nu10121860,0.0,0.0,7.542000000000001,0.12600000000000003,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7181000000000001,0.038,0.2357,0.0458,14.0,10.0,4.0,43.0,0
NAA,2018_ford_10,2,10.3390/nu10121860,0.0,0.0,7.524,0.18000000000000002,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7239,0.0435,0.23550000000000001,0.0489,17.0,11.0,6.0,43.0,0
NAA,2018_white_43,2,10.1038/s41386-018-0027-7,0.0,0.0,7.488,0.639,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
NAA,2018_white_43,3,10.1038/s41386-018-0027-7,0.0,0.0,7.38,0.5850000000000001,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
NAA,2018_white_43,1,10.1038/s41386-018-0027-7,0.0,0.0,7.362,0.747,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
NAA,2019_bustillo_246,1,10.1016/j.jad.2018.12.064,0.0,0.0,17.19,1.26,17.19,1.26,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
NAA,2019_bustillo_246,3,10.1016/j.jad.2018.12.064,0.0,0.0,17.1,1.53,17.1,1.53,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
NAA,2020_blest-hopley_25,2,10.1111/adb.12827,0.0,0.0,8.2863,0.9810000000000001,0.0,0.0,Control,GM,Adolescent-onset heavy cannabis use associated with significantly reduced glial but not neuronal markers and glutamate levels in the hippocampus.,0.6365,0.058,0.3099,0.098,21.0,12.0,9.0,24.24,4.11
NAA,2020_lind_40,1,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,8.739,0.513,8.739,0.513,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.64669,0.0,0.23431000000000002,0.0,20.0,10.0,10.0,22.6,2.37
NAA,2020_lind_40,10,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,11.277,1.0080000000000002,11.277,1.0080000000000002,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.6731999999999999,0.0,0.3268,0.0,20.0,10.0,10.0,22.6,2.37
NAA,2020_tran_30,1,10.1111/jon.12728,1.51,0.1,0.0,0.0,0.0,0.0,Control,GM,Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis.,0.0,0.0,0.0,0.0,16.0,6.0,10.0,57.8,11.7
NAA,2021_steinegger_26,1,10.1111/adb.13027,0.0,0.0,8.217,0.6930000000000001,8.217,0.6930000000000001,Control,GM,Neurometabolic alterations in the nucleus accumbens of smokers assessed with H-1 magnetic resonance spectroscopy: The role of glutamate and neuroinflammation,0.8075,0.058899999999999994,0.1925,0.058899999999999994,25.0,0.0,20.0,26.3,4.27
NAAG,2018_burger_185,17,10.1016/j.drugalcdep.2017.11.029,1.417,0.167,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
NAAG,2018_burger_185,18,10.1016/j.drugalcdep.2017.11.029,1.574,0.2,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
NAAG,2018_egerton_23,10,10.1038/s41380-018-0082-9,1.65,0.18,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
NAAG,2018_egerton_23,11,10.1038/s41380-018-0082-9,1.54,0.16,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
NAAG,2018_egerton_23,12,10.1038/s41380-018-0082-9,1.53,0.1,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
NAAG,2018_egerton_23,4,10.1038/s41380-018-0082-9,1.61,0.18,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
NAAG,2018_egerton_23,5,10.1038/s41380-018-0082-9,1.54,0.19,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
NAAG,2018_egerton_23,6,10.1038/s41380-018-0082-9,1.55,0.19,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
NAAG,2018_plitman_273,2,10.1016/j.pscychresns.2018.01.004,0.0,0.0,2.011875,0.11249999999999999,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
NAAG,2018_plitman_273,5,10.1016/j.pscychresns.2018.01.004,0.0,0.0,2.0681249999999998,0.18,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
NAAG,2018_plitman_273,6,10.1016/j.pscychresns.2018.01.004,0.0,0.0,2.0100000000000002,0.136875,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
NAAG,2018_veeramuthu_25,3,10.1016/j.acra.2018.01.005,2.059,0.11,0.67875,0.066,0.0,0.0,Control,WM,Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI): An In Vivo Proton Magnetic Resonance Spectroscopy (1H-MRS) Study.,0.0,0.0,0.0,0.0,13.0,5.0,8.0,27.15,4.88
NAAG,2019_bustillo_246,2,10.1016/j.jad.2018.12.064,0.0,0.0,3.2624999999999997,0.22499999999999998,3.2624999999999997,0.22499999999999998,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
NAAG,2019_bustillo_246,4,10.1016/j.jad.2018.12.064,0.0,0.0,3.2624999999999997,0.26249999999999996,3.2624999999999997,0.26249999999999996,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
NAAG,2019_ferland_237,1,10.1007/s00221-019-05691-z,0.0,0.0,4.17525,0.088125,4.17525,0.088125,Healthy,WM,Longitudinal assessment of (1)H-MRS (GABA and Glx) and TMS measures of cortical inhibition and facilitation in the sensorimotor cortex.,0.22399999999999998,0.04,0.743,0.048,10.0,5.0,5.0,26.0,4
NAAG,2019_ferland_237,2,10.1007/s00221-019-05691-z,0.0,0.0,4.156875,0.142125,4.156875,0.142125,Healthy,WM,Longitudinal assessment of (1)H-MRS (GABA and Glx) and TMS measures of cortical inhibition and facilitation in the sensorimotor cortex.,0.22399999999999998,0.052000000000000005,0.742,0.057999999999999996,10.0,5.0,5.0,26.0,4
NAAG,2019_monnig_54,1,10.1093/alcalc/agz062,1.61,0.113,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolites on the Descending Limb of Acute Alcohol: A Preliminary 1H MRS Study.,0.0,0.0,0.0,0.0,13.0,8.0,5.0,26.4,2.8
NAAG,2019_wiegers_62,1,10.1007/s00125-019-4862-9,0.0,0.0,2.085,0.10312500000000001,2.085,0.10312500000000001,Control,WM,Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status.,0.265,0.042,0.713,0.047,13.0,7.0,6.0,25.5,5.5
NAAG,2020_lind_40,4,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,2.075625,0.135,2.075625,0.135,Control,WM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.29254,0.0,0.66486,0.0,20.0,10.0,10.0,22.6,2.37
NAAG,2020_tran_30,2,10.1111/jon.12728,1.82,0.23,0.0,0.0,0.0,0.0,Control,WM,Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis.,0.0,0.0,0.0,0.0,16.0,6.0,10.0,57.8,11.7
NAAG,2018_egerton_23,7,10.1038/s41380-018-0082-9,1.26,0.15,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
NAAG,2018_egerton_23,8,10.1038/s41380-018-0082-9,1.24,0.07,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
NAAG,2018_egerton_23,9,10.1038/s41380-018-0082-9,1.17,0.04,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
NAAG,2018_egerton_23,1,10.1038/s41380-018-0082-9,1.24,0.11,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
NAAG,2018_egerton_23,2,10.1038/s41380-018-0082-9,1.23,0.09,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
NAAG,2018_egerton_23,3,10.1038/s41380-018-0082-9,1.2,0.07,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
NAAG,2018_evans_43,1,10.1038/s41386-018-0057-1,1.58,0.02,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
NAAG,2018_evans_43,2,10.1038/s41386-018-0057-1,1.57,0.03,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
NAAG,2018_evans_43,3,10.1038/s41386-018-0057-1,1.66,0.03,0.0,0.0,0.0,0.0,Control,GM,7T (1)H-MRS in major depressive disorder: a Ketamine Treatment Study.,0.6,0.08,0.18,0.04,17.0,12.0,5.0,34.7,2.9
NAAG,2018_ford_10,4,10.3390/nu10121860,0.0,0.0,0.7542000000000001,0.012600000000000004,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7181000000000001,0.038,0.2357,0.0458,14.0,10.0,4.0,43.0,0
NAAG,2018_ford_10,2,10.3390/nu10121860,0.0,0.0,0.7524000000000001,0.018000000000000002,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7239,0.0435,0.23550000000000001,0.0489,17.0,11.0,6.0,43.0,0
NAAG,2018_white_43,2,10.1038/s41386-018-0027-7,0.0,0.0,0.7488000000000001,0.0639,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
NAAG,2018_white_43,3,10.1038/s41386-018-0027-7,0.0,0.0,0.738,0.05850000000000001,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
NAAG,2018_white_43,1,10.1038/s41386-018-0027-7,0.0,0.0,0.7362000000000001,0.0747,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
NAAG,2019_bustillo_246,1,10.1016/j.jad.2018.12.064,0.0,0.0,1.7190000000000003,0.126,1.7190000000000003,0.126,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
NAAG,2019_bustillo_246,3,10.1016/j.jad.2018.12.064,0.0,0.0,1.7100000000000002,0.15300000000000002,1.7100000000000002,0.15300000000000002,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
NAAG,2020_blest-hopley_25,2,10.1111/adb.12827,0.0,0.0,0.8286300000000001,0.09810000000000002,0.0,0.0,Control,GM,Adolescent-onset heavy cannabis use associated with significantly reduced glial but not neuronal markers and glutamate levels in the hippocampus.,0.6365,0.058,0.3099,0.098,21.0,12.0,9.0,24.24,4.11
NAAG,2020_lind_40,1,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,0.8739000000000001,0.051300000000000005,0.8739000000000001,0.051300000000000005,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.64669,0.0,0.23431000000000002,0.0,20.0,10.0,10.0,22.6,2.37
NAAG,2020_lind_40,10,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,1.1277,0.10080000000000003,1.1277,0.10080000000000003,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.6731999999999999,0.0,0.3268,0.0,20.0,10.0,10.0,22.6,2.37
NAAG,2020_tran_30,1,10.1111/jon.12728,1.51,0.1,0.0,0.0,0.0,0.0,Control,GM,Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis.,0.0,0.0,0.0,0.0,16.0,6.0,10.0,57.8,11.7
NAAG,2021_steinegger_26,1,10.1111/adb.13027,0.0,0.0,0.8217000000000001,0.06930000000000001,0.8217000000000001,0.06930000000000001,Control,GM,Neurometabolic alterations in the nucleus accumbens of smokers assessed with H-1 magnetic resonance spectroscopy: The role of glutamate and neuroinflammation,0.8075,0.058899999999999994,0.1925,0.058899999999999994,25.0,0.0,20.0,26.3,4.27
Glu,2017_bustillo_43,1,10.1093/schbul/sbw122,0.0,0.0,10.296,1.584,10.296,1.584,Control,WM,Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample.,0.37,0.17,0.63,0.0,97.0,69.0,28.0,37.1,12.3
Glu,2018_burger_185,17,10.1016/j.drugalcdep.2017.11.029,1.319,0.212,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
Glu,2018_burger_185,18,10.1016/j.drugalcdep.2017.11.029,1.404,0.347,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
Glu,2018_caravaggio_28,1,10.1016/j.euroneuro.2017.12.002,0.0,0.0,8.1642,1.2078000000000002,0.0,0.0,Healthy,WM,Reduced insulin sensitivity may be related to less striatal glutamate: An (1)H-MRS study in healthy non-obese humans.,0.2921,0.0391,0.6297999999999999,0.0621,17.0,9.0,8.0,28.35,9.53
Glu,2018_caravaggio_28,2,10.1016/j.euroneuro.2017.12.002,0.0,0.0,7.9068000000000005,1.4520000000000002,0.0,0.0,Healthy,WM,Reduced insulin sensitivity may be related to less striatal glutamate: An (1)H-MRS study in healthy non-obese humans.,0.2465,0.028399999999999998,0.6658,0.06709999999999999,17.0,9.0,8.0,28.35,9.53
Glu,2018_egerton_23,10,10.1038/s41380-018-0082-9,1.28,0.27,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,11,10.1038/s41380-018-0082-9,1.79,0.3,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,12,10.1038/s41380-018-0082-9,1.31,0.43,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,4,10.1038/s41380-018-0082-9,1.37,0.31,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,5,10.1038/s41380-018-0082-9,1.54,0.17,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,6,10.1038/s41380-018-0082-9,1.43,0.4,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
Glu,2018_plitman_273,2,10.1016/j.pscychresns.2018.01.004,0.0,0.0,10.4478,1.1748,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
Glu,2018_plitman_273,5,10.1016/j.pscychresns.2018.01.004,0.0,0.0,10.5798,1.518,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
Glu,2018_plitman_273,6,10.1016/j.pscychresns.2018.01.004,0.0,0.0,10.9692,1.0296,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
Glu,2018_veeramuthu_25,3,10.1016/j.acra.2018.01.005,2.051,0.336,2.39844,0.21648,0.0,0.0,Control,WM,Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI): An In Vivo Proton Magnetic Resonance Spectroscopy (1H-MRS) Study.,0.0,0.0,0.0,0.0,13.0,5.0,8.0,27.15,4.88
Glu,2019_bustillo_246,2,10.1016/j.jad.2018.12.064,0.0,0.0,9.57,1.518,9.57,1.518,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
Glu,2019_bustillo_246,4,10.1016/j.jad.2018.12.064,0.0,0.0,10.23,2.31,10.23,2.31,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
Glu,2019_ferland_237,1,10.1007/s00221-019-05691-z,0.85,0.137,9.566699999999999,0.8131200000000001,9.566699999999999,0.8131200000000001,Healthy,WM,Longitudinal assessment of (1)H-MRS (GABA and Glx) and TMS measures of cortical inhibition and facilitation in the sensorimotor cortex.,0.22399999999999998,0.04,0.743,0.048,10.0,5.0,5.0,26.0,4
Glu,2019_ferland_237,2,10.1007/s00221-019-05691-z,0.803,0.05,9.3588,0.4818,9.3588,0.4818,Healthy,WM,Longitudinal assessment of (1)H-MRS (GABA and Glx) and TMS measures of cortical inhibition and facilitation in the sensorimotor cortex.,0.22399999999999998,0.052000000000000005,0.742,0.057999999999999996,10.0,5.0,5.0,26.0,4
Glu,2019_kaplan_160,1,10.1097/j.pain.0000000000001480,0.0,0.0,7.240200000000001,0.9768,0.0,0.0,Control,WM,Functional and neurochemical disruptions of brain hub topology in chronic pain.,0.3259,0.08,0.6334000000000001,0.08,46.0,0.0,0.0,38.83,12.18
Glu,2019_monnig_54,1,10.1093/alcalc/agz062,1.402,0.125,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolites on the Descending Limb of Acute Alcohol: A Preliminary 1H MRS Study.,0.0,0.0,0.0,0.0,13.0,8.0,5.0,26.4,2.8
Glu,2019_schmitz_49,1,10.1111/apt.15256,0.0,0.0,3.5448600000000003,1.07844,0.0,0.0,Control,WM,Brain metabolic alterations in patients with long-term calcineurin inhibitor therapy after liver transplantation.,0.0,0.0,0.0,0.0,32.0,17.0,15.0,58.6,7.7
Glu,2020_burger_51,11,10.1111/ejn.14583,1.16,0.22,0.0,0.0,0.0,0.0,Healthy,WM,The relationship between measurement of in vivo brain glutamate and markers of iron metabolism: A proton magnetic resonance spectroscopy study in healthy adults.,0.0,0.0,0.0,0.0,20.0,0.0,20.0,31.9,5.2
Glu,2020_burger_51,12,10.1111/ejn.14583,1.19,0.22,0.0,0.0,0.0,0.0,Healthy,WM,The relationship between measurement of in vivo brain glutamate and markers of iron metabolism: A proton magnetic resonance spectroscopy study in healthy adults.,0.0,0.0,0.0,0.0,20.0,0.0,20.0,31.9,5.2
Glu,2018_bossong_21,1,10.1093/ijnp/pyy011,0.0,0.0,6.567,1.2936,0.0,0.0,Healthy,GM,Human Striatal Response to Reward Anticipation Linked to Hippocampal Glutamate Levels,0.66,0.05,0.0995,0.0196,19.0,9.0,10.0,25.8,5.6
Glu,2018_chiu_193,4,10.1016/j.schres.2017.07.021,0.0,0.0,5.2008,0.9174,5.2008,0.9174,Control,GM,In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study.,0.6076,0.0858,0.2432,0.0821,14.0,5.0,9.0,27.71,5.88
Glu,2018_egerton_23,7,10.1038/s41380-018-0082-9,1.86,0.31,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,8,10.1038/s41380-018-0082-9,1.71,0.22,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,9,10.1038/s41380-018-0082-9,1.42,0.15,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,1,10.1038/s41380-018-0082-9,1.94,0.24,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,2,10.1038/s41380-018-0082-9,1.54,0.23,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
Glu,2018_egerton_23,3,10.1038/s41380-018-0082-9,1.6,0.23,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
Glu,2018_ford_10,4,10.3390/nu10121860,0.0,0.0,7.801200000000001,0.42240000000000005,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7181000000000001,0.038,0.2357,0.0458,14.0,10.0,4.0,43.0,0
Glu,2018_ford_10,2,10.3390/nu10121860,0.0,0.0,7.5504,0.3102,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7239,0.0435,0.23550000000000001,0.0489,17.0,11.0,6.0,43.0,0
Glu,2018_shakory_43,1,10.1038/s41386-018-0163-0,0.0,0.0,8.995800000000001,1.0230000000000001,0.0,0.0,Control,GM,Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.,0.6,0.11,0.35,0.091,31.0,18.0,13.0,22.2,3.1
Glu,2018_shakory_43,8,10.1038/s41386-018-0163-0,0.0,0.0,8.943000000000001,1.1484,0.0,0.0,Control,GM,Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.,0.6,0.11,0.35,0.091,18.0,0.0,0.0,22.2,3.1
Glu,2018_shakory_43,9,10.1038/s41386-018-0163-0,0.0,0.0,9.075000000000001,0.8580000000000001,0.0,0.0,Control,GM,Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.,0.6,0.11,0.35,0.091,13.0,0.0,0.0,22.2,3.1
Glu,2018_soeiro-de-souza_3,1,10.1016/j.bpsc.2018.02.007,1.03,0.14,0.0,0.0,0.0,0.0,Control,GM,Anterior Cingulate Cortex Glutamatergic Metabolites and Mood Stabilizers in Euthymic Bipolar I Disorder Patients: A Proton Magnetic Resonance Spectroscopy Study.,0.6308,0.04,0.175,0.03,80.0,42.0,38.0,28.13,8.19
Glu,2018_white_43,2,10.1038/s41386-018-0027-7,0.0,0.0,9.1806,0.9966,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
Glu,2018_white_43,3,10.1038/s41386-018-0027-7,0.0,0.0,8.6856,0.9834,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
Glu,2018_white_43,1,10.1038/s41386-018-0027-7,0.0,0.0,8.5272,0.9504,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
Glu,2019_bossong_76,1,10.1001/jamapsychiatry.2018.3252,0.0,0.0,7.6626,1.4718,7.6626,1.4718,Control,GM,Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis.,0.64,0.07,0.33,0.08,30.0,16.0,14.0,24.7,3.8
Glu,2019_bustillo_246,1,10.1016/j.jad.2018.12.064,0.0,0.0,16.698,2.178,16.698,2.178,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
Glu,2019_bustillo_246,3,10.1016/j.jad.2018.12.064,0.0,0.0,17.226000000000003,3.1020000000000003,17.226000000000003,3.1020000000000003,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
Glu,2019_chan_14,1,10.1371/journal.pone.0208666,0.0,0.0,1.25532,0.17754000000000003,0.0,0.0,Control,GM,Relating excitatory and inhibitory neurochemicals to visual perception: A magnetic resonance study of occipital cortex between migraine events,0.643,0.037,0.23,0.034,16.0,8.0,8.0,27.125,4.63
Glu,2019_jelen_29,1,10.1016/j.euroneuro.2018.12.005,1.109,0.167,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Glu,2019_jelen_29,4,10.1016/j.euroneuro.2018.12.005,1.039,0.097,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Glu,2019_jelen_29,7,10.1016/j.euroneuro.2018.12.005,1.016,0.099,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Glu,2019_jelen_29,10,10.1016/j.euroneuro.2018.12.005,1.153,0.122,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Glu,2019_jelen_29,13,10.1016/j.euroneuro.2018.12.005,1.05,0.116,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Glu,2019_jelen_29,16,10.1016/j.euroneuro.2018.12.005,1.094,0.174,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Glu,2020_bell_34,1,10.1002/nbm.4245,0.0,0.0,12.408000000000001,1.518,12.408000000000001,1.518,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,2,10.1002/nbm.4245,0.0,0.0,8.646,0.99,8.646,0.99,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,3,10.1002/nbm.4245,0.0,0.0,10.296,1.98,10.296,1.98,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,4,10.1002/nbm.4245,0.0,0.0,9.108,0.792,9.108,0.792,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,5,10.1002/nbm.4245,0.0,0.0,8.448,1.4520000000000002,8.448,1.4520000000000002,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,6,10.1002/nbm.4245,0.0,0.0,6.336,0.66,6.336,0.66,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,7,10.1002/nbm.4245,0.0,0.0,4.884,0.46199999999999997,4.884,0.46199999999999997,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,8,10.1002/nbm.4245,0.0,0.0,4.026,0.33,4.026,0.33,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,9,10.1002/nbm.4245,0.0,0.0,1.914,0.33,1.914,0.33,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_bell_34,10,10.1002/nbm.4245,0.0,0.0,1.8479999999999999,0.264,1.8479999999999999,0.264,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Glu,2020_poletti_11,2,10.3389/fpsyt.2020.590095,0.0,0.0,6.072,0.7722,0.0,0.0,Control,GM,Proinflammatory Cytokines Predict Brain Metabolite Concentrations in the Anterior Cingulate Cortex of Patients With Bipolar Disorder,0.7745000000000001,0.0795,0.8101999999999999,0.10279999999999999,49.0,21.0,28.0,33.7,11.14
Glu,2021_bednarik_15,1,10.3389/fnins.2021.609485,0.0,0.0,8.1048,0.2838,8.1048,0.2838,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7240000000000001,0.0178,0.18600000000000003,0.031,12.0,0.0,12.0,26.0,5
Glu,2021_bednarik_15,2,10.3389/fnins.2021.609485,0.0,0.0,7.986,0.2838,7.986,0.2838,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7340000000000001,0.018000000000000002,0.17800000000000002,0.032,12.0,0.0,12.0,26.0,5
Glu,2021_gajdosik_34,1,10.1002/nbm.4538,0.0,0.0,7.3919999999999995,1.1880000000000002,7.3919999999999995,1.1880000000000002,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,2.0,1.0,32.5,10.2
Glu,2021_gajdosik_34,2,10.1002/nbm.4538,0.0,0.0,7.854000000000001,0.264,7.854000000000001,0.264,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,1.0,2.0,32.5,10.2
Glu,2021_steinegger_26,1,10.1111/adb.13027,0.0,0.0,11.226600000000001,1.6896000000000002,11.226600000000001,1.6896000000000002,Control,GM,Neurometabolic alterations in the nucleus accumbens of smokers assessed with H-1 magnetic resonance spectroscopy: The role of glutamate and neuroinflammation,0.8075,0.058899999999999994,0.1925,0.058899999999999994,25.0,0.0,20.0,26.3,4.27
Gln,2017_bustillo_43,1,10.1093/schbul/sbw122,0.0,0.0,3.39768,0.5227200000000001,3.39768,0.5227200000000001,Control,WM,Glutamatergic and Neuronal Dysfunction in Gray and White Matter: A Spectroscopic Imaging Study in a Large Schizophrenia Sample.,0.37,0.17,0.63,0.0,97.0,69.0,28.0,37.1,12.3
Gln,2018_burger_185,17,10.1016/j.drugalcdep.2017.11.029,1.319,0.212,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
Gln,2018_burger_185,18,10.1016/j.drugalcdep.2017.11.029,1.404,0.347,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
Gln,2018_caravaggio_28,1,10.1016/j.euroneuro.2017.12.002,0.0,0.0,2.6941859999999997,0.3985740000000001,0.0,0.0,Healthy,WM,Reduced insulin sensitivity may be related to less striatal glutamate: An (1)H-MRS study in healthy non-obese humans.,0.2921,0.0391,0.6297999999999999,0.0621,17.0,9.0,8.0,28.35,9.53
Gln,2018_caravaggio_28,2,10.1016/j.euroneuro.2017.12.002,0.0,0.0,2.6092440000000003,0.4791600000000001,0.0,0.0,Healthy,WM,Reduced insulin sensitivity may be related to less striatal glutamate: An (1)H-MRS study in healthy non-obese humans.,0.2465,0.028399999999999998,0.6658,0.06709999999999999,17.0,9.0,8.0,28.35,9.53
Gln,2018_egerton_23,10,10.1038/s41380-018-0082-9,1.28,0.27,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
Gln,2018_egerton_23,11,10.1038/s41380-018-0082-9,1.79,0.3,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
Gln,2018_egerton_23,12,10.1038/s41380-018-0082-9,1.31,0.43,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
Gln,2018_egerton_23,4,10.1038/s41380-018-0082-9,1.37,0.31,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
Gln,2018_egerton_23,5,10.1038/s41380-018-0082-9,1.54,0.17,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
Gln,2018_egerton_23,6,10.1038/s41380-018-0082-9,1.43,0.4,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
Gln,2018_plitman_273,2,10.1016/j.pscychresns.2018.01.004,0.0,0.0,3.4477740000000003,0.38768400000000003,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
Gln,2018_plitman_273,5,10.1016/j.pscychresns.2018.01.004,0.0,0.0,3.491334,0.50094,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
Gln,2018_plitman_273,6,10.1016/j.pscychresns.2018.01.004,0.0,0.0,3.6198360000000003,0.339768,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
Gln,2018_veeramuthu_25,3,10.1016/j.acra.2018.01.005,2.051,0.336,0.7914852,0.0714384,0.0,0.0,Control,WM,Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI): An In Vivo Proton Magnetic Resonance Spectroscopy (1H-MRS) Study.,0.0,0.0,0.0,0.0,13.0,5.0,8.0,27.15,4.88
Gln,2019_bustillo_246,2,10.1016/j.jad.2018.12.064,0.0,0.0,3.1581,0.50094,3.1581,0.50094,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
Gln,2019_bustillo_246,4,10.1016/j.jad.2018.12.064,0.0,0.0,3.3759,0.7623000000000001,3.3759,0.7623000000000001,Control,WM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.16,0.06,0.81,0.0,45.0,19.0,26.0,39.1,11.9
Gln,2019_ferland_237,1,10.1007/s00221-019-05691-z,0.85,0.137,3.157011,0.26832960000000006,3.157011,0.26832960000000006,Healthy,WM,Longitudinal assessment of (1)H-MRS (GABA and Glx) and TMS measures of cortical inhibition and facilitation in the sensorimotor cortex.,0.22399999999999998,0.04,0.743,0.048,10.0,5.0,5.0,26.0,4
Gln,2019_ferland_237,2,10.1007/s00221-019-05691-z,0.803,0.05,3.088404,0.158994,3.088404,0.158994,Healthy,WM,Longitudinal assessment of (1)H-MRS (GABA and Glx) and TMS measures of cortical inhibition and facilitation in the sensorimotor cortex.,0.22399999999999998,0.052000000000000005,0.742,0.057999999999999996,10.0,5.0,5.0,26.0,4
Gln,2019_kaplan_160,1,10.1097/j.pain.0000000000001480,0.0,0.0,2.389266,0.322344,0.0,0.0,Control,WM,Functional and neurochemical disruptions of brain hub topology in chronic pain.,0.3259,0.08,0.6334000000000001,0.08,46.0,0.0,0.0,38.83,12.18
Gln,2019_monnig_54,1,10.1093/alcalc/agz062,1.402,0.125,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolites on the Descending Limb of Acute Alcohol: A Preliminary 1H MRS Study.,0.0,0.0,0.0,0.0,13.0,8.0,5.0,26.4,2.8
Gln,2019_schmitz_49,1,10.1111/apt.15256,0.0,0.0,1.1698038000000002,0.3558852,0.0,0.0,Control,WM,Brain metabolic alterations in patients with long-term calcineurin inhibitor therapy after liver transplantation.,0.0,0.0,0.0,0.0,32.0,17.0,15.0,58.6,7.7
Gln,2020_burger_51,11,10.1111/ejn.14583,1.16,0.22,0.0,0.0,0.0,0.0,Healthy,WM,The relationship between measurement of in vivo brain glutamate and markers of iron metabolism: A proton magnetic resonance spectroscopy study in healthy adults.,0.0,0.0,0.0,0.0,20.0,0.0,20.0,31.9,5.2
Gln,2020_burger_51,12,10.1111/ejn.14583,1.19,0.22,0.0,0.0,0.0,0.0,Healthy,WM,The relationship between measurement of in vivo brain glutamate and markers of iron metabolism: A proton magnetic resonance spectroscopy study in healthy adults.,0.0,0.0,0.0,0.0,20.0,0.0,20.0,31.9,5.2
Gln,2018_bossong_21,1,10.1093/ijnp/pyy011,0.0,0.0,2.16711,0.42688800000000005,0.0,0.0,Healthy,GM,Human Striatal Response to Reward Anticipation Linked to Hippocampal Glutamate Levels,0.66,0.05,0.0995,0.0196,19.0,9.0,10.0,25.8,5.6
Gln,2018_chiu_193,4,10.1016/j.schres.2017.07.021,0.0,0.0,1.716264,0.302742,1.716264,0.302742,Control,GM,In vivo gamma-aminobutyric acid and glutamate levels in people with first-episode schizophrenia: A proton magnetic resonance spectroscopy study.,0.6076,0.0858,0.2432,0.0821,14.0,5.0,9.0,27.71,5.88
Gln,2018_egerton_23,7,10.1038/s41380-018-0082-9,1.86,0.31,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
Gln,2018_egerton_23,8,10.1038/s41380-018-0082-9,1.71,0.22,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
Gln,2018_egerton_23,9,10.1038/s41380-018-0082-9,1.42,0.15,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
Gln,2018_egerton_23,1,10.1038/s41380-018-0082-9,1.94,0.24,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
Gln,2018_egerton_23,2,10.1038/s41380-018-0082-9,1.54,0.23,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
Gln,2018_egerton_23,3,10.1038/s41380-018-0082-9,1.6,0.23,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
Gln,2018_ford_10,4,10.3390/nu10121860,0.0,0.0,2.574396,0.13939200000000002,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7181000000000001,0.038,0.2357,0.0458,14.0,10.0,4.0,43.0,0
Gln,2018_ford_10,2,10.3390/nu10121860,0.0,0.0,2.491632,0.102366,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7239,0.0435,0.23550000000000001,0.0489,17.0,11.0,6.0,43.0,0
Gln,2018_shakory_43,1,10.1038/s41386-018-0163-0,0.0,0.0,2.9686140000000005,0.33759000000000006,0.0,0.0,Control,GM,Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.,0.6,0.11,0.35,0.091,31.0,18.0,13.0,22.2,3.1
Gln,2018_shakory_43,8,10.1038/s41386-018-0163-0,0.0,0.0,2.9511900000000004,0.37897200000000003,0.0,0.0,Control,GM,Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.,0.6,0.11,0.35,0.091,18.0,0.0,0.0,22.2,3.1
Gln,2018_shakory_43,9,10.1038/s41386-018-0163-0,0.0,0.0,2.9947500000000007,0.28314000000000006,0.0,0.0,Control,GM,Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.,0.6,0.11,0.35,0.091,13.0,0.0,0.0,22.2,3.1
Gln,2018_soeiro-de-souza_3,1,10.1016/j.bpsc.2018.02.007,1.03,0.14,0.0,0.0,0.0,0.0,Control,GM,Anterior Cingulate Cortex Glutamatergic Metabolites and Mood Stabilizers in Euthymic Bipolar I Disorder Patients: A Proton Magnetic Resonance Spectroscopy Study.,0.6308,0.04,0.175,0.03,80.0,42.0,38.0,28.13,8.19
Gln,2018_white_43,2,10.1038/s41386-018-0027-7,0.0,0.0,3.029598,0.328878,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
Gln,2018_white_43,3,10.1038/s41386-018-0027-7,0.0,0.0,2.8662480000000006,0.32452200000000003,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
Gln,2018_white_43,1,10.1038/s41386-018-0027-7,0.0,0.0,2.8139760000000003,0.313632,0.0,0.0,Healthy,GM,"Psychostimulant drug effects on glutamate, Glx, and creatine in the anterior cingulate cortex and subjective response in healthy humans.",0.7,0.06,0.13,0.09,26.0,13.0,13.0,22.3,3.27
Gln,2019_bossong_76,1,10.1001/jamapsychiatry.2018.3252,0.0,0.0,2.528658,0.485694,2.528658,0.485694,Control,GM,Association of Hippocampal Glutamate Levels With Adverse Outcomes in Individuals at Clinical High Risk for Psychosis.,0.64,0.07,0.33,0.08,30.0,16.0,14.0,24.7,3.8
Gln,2019_bustillo_246,1,10.1016/j.jad.2018.12.064,0.0,0.0,5.51034,0.71874,5.51034,0.71874,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
Gln,2019_bustillo_246,3,10.1016/j.jad.2018.12.064,0.0,0.0,5.684580000000001,1.0236600000000002,5.684580000000001,1.0236600000000002,Control,GM,Proton magnetic resonance spectroscopic imaging of gray and white matter in bipolar-I and schizophrenia.,0.81,0.06,0.16,0.0,45.0,19.0,26.0,39.1,11.9
Gln,2019_chan_14,1,10.1371/journal.pone.0208666,0.0,0.0,0.4142556,0.058588200000000014,0.0,0.0,Control,GM,Relating excitatory and inhibitory neurochemicals to visual perception: A magnetic resonance study of occipital cortex between migraine events,0.643,0.037,0.23,0.034,16.0,8.0,8.0,27.125,4.63
Gln,2019_jelen_29,1,10.1016/j.euroneuro.2018.12.005,1.109,0.167,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Gln,2019_jelen_29,4,10.1016/j.euroneuro.2018.12.005,1.039,0.097,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Gln,2019_jelen_29,7,10.1016/j.euroneuro.2018.12.005,1.016,0.099,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Gln,2019_jelen_29,10,10.1016/j.euroneuro.2018.12.005,1.153,0.122,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Gln,2019_jelen_29,13,10.1016/j.euroneuro.2018.12.005,1.05,0.116,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Gln,2019_jelen_29,16,10.1016/j.euroneuro.2018.12.005,1.094,0.174,0.0,0.0,0.0,0.0,Control,GM,Functional magnetic resonance spectroscopy in patients with schizophrenia and bipolar affective disorder: Glutamate dynamics in the anterior cingulate cortex during a working memory task.,0.6579999999999999,0.035,0.153,0.033,14.0,7.0,7.0,33.8,10.5
Gln,2020_bell_34,1,10.1002/nbm.4245,0.0,0.0,4.094640000000001,0.50094,4.094640000000001,0.50094,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Gln,2020_bell_34,2,10.1002/nbm.4245,0.0,0.0,2.8531800000000005,0.3267,2.8531800000000005,0.3267,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Gln,2020_bell_34,3,10.1002/nbm.4245,0.0,0.0,3.39768,0.6534,3.39768,0.6534,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Gln,2020_bell_34,4,10.1002/nbm.4245,0.0,0.0,3.0056400000000005,0.26136000000000004,3.0056400000000005,0.26136000000000004,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Gln,2020_bell_34,5,10.1002/nbm.4245,0.0,0.0,2.78784,0.4791600000000001,2.78784,0.4791600000000001,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Gln,2020_bell_34,6,10.1002/nbm.4245,0.0,0.0,2.0908800000000003,0.21780000000000002,2.0908800000000003,0.21780000000000002,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Gln,2020_bell_34,7,10.1002/nbm.4245,0.0,0.0,1.6117200000000003,0.15245999999999998,1.6117200000000003,0.15245999999999998,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Gln,2020_bell_34,8,10.1002/nbm.4245,0.0,0.0,1.32858,0.10890000000000001,1.32858,0.10890000000000001,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Gln,2020_bell_34,9,10.1002/nbm.4245,0.0,0.0,0.63162,0.10890000000000001,0.63162,0.10890000000000001,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Gln,2020_bell_34,10,10.1002/nbm.4245,0.0,0.0,0.6098399999999999,0.08712,0.6098399999999999,0.08712,Healthy,GM,In Vivo Glx and Glu Measurements from GABA-Edited MRS at 3T,0.78,0.0,0.65,0.0,15.0,0.0,15.0,24.0,0
Gln,2020_poletti_11,2,10.3389/fpsyt.2020.590095,0.0,0.0,2.00376,0.254826,0.0,0.0,Control,GM,Proinflammatory Cytokines Predict Brain Metabolite Concentrations in the Anterior Cingulate Cortex of Patients With Bipolar Disorder,0.7745000000000001,0.0795,0.8101999999999999,0.10279999999999999,49.0,21.0,28.0,33.7,11.14
Gln,2021_bednarik_15,1,10.3389/fnins.2021.609485,0.0,0.0,2.674584,0.093654,2.674584,0.093654,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7240000000000001,0.0178,0.18600000000000003,0.031,12.0,0.0,12.0,26.0,5
Gln,2021_bednarik_15,2,10.3389/fnins.2021.609485,0.0,0.0,2.63538,0.093654,2.63538,0.093654,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7340000000000001,0.018000000000000002,0.17800000000000002,0.032,12.0,0.0,12.0,26.0,5
Gln,2021_gajdosik_34,1,10.1002/nbm.4538,0.0,0.0,2.4393599999999998,0.39204000000000006,2.4393599999999998,0.39204000000000006,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,2.0,1.0,32.5,10.2
Gln,2021_gajdosik_34,2,10.1002/nbm.4538,0.0,0.0,2.5918200000000002,0.08712,2.5918200000000002,0.08712,Healthy,GM,Hippocampal single-voxel MR spectroscopy with a long echo time at 3 T using semi-LASER sequence,0.659,0.023,0.289,0.036000000000000004,6.0,1.0,2.0,32.5,10.2
Gln,2021_steinegger_26,1,10.1111/adb.13027,0.0,0.0,3.7047780000000006,0.5575680000000001,3.7047780000000006,0.5575680000000001,Control,GM,Neurometabolic alterations in the nucleus accumbens of smokers assessed with H-1 magnetic resonance spectroscopy: The role of glutamate and neuroinflammation,0.8075,0.058899999999999994,0.1925,0.058899999999999994,25.0,0.0,20.0,26.3,4.27
PCh,2018_burger_185,17,10.1016/j.drugalcdep.2017.11.029,0.291,0.043,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
PCh,2018_burger_185,18,10.1016/j.drugalcdep.2017.11.029,0.308,0.032,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
PCh,2018_egerton_23,10,10.1038/s41380-018-0082-9,0.3,0.03,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
PCh,2018_egerton_23,11,10.1038/s41380-018-0082-9,0.3,0.03,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
PCh,2018_egerton_23,12,10.1038/s41380-018-0082-9,0.31,0.02,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
PCh,2018_egerton_23,4,10.1038/s41380-018-0082-9,0.28,0.03,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
PCh,2018_egerton_23,5,10.1038/s41380-018-0082-9,0.3,0.04,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
PCh,2018_egerton_23,6,10.1038/s41380-018-0082-9,0.32,0.04,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
PCh,2018_plitman_273,2,10.1016/j.pscychresns.2018.01.004,0.0,0.0,0.8999999999999999,0.12375,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
PCh,2018_plitman_273,5,10.1016/j.pscychresns.2018.01.004,0.0,0.0,0.9412499999999999,0.13874999999999998,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
PCh,2018_plitman_273,6,10.1016/j.pscychresns.2018.01.004,0.0,0.0,0.92625,0.14250000000000002,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
PCh,2018_veeramuthu_25,3,10.1016/j.acra.2018.01.005,0.374,0.049,0.2475,0.040875,0.0,0.0,Control,WM,Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI): An In Vivo Proton Magnetic Resonance Spectroscopy (1H-MRS) Study.,0.0,0.0,0.0,0.0,13.0,5.0,8.0,27.15,4.88
PCh,2019_khomenko_49,1,10.1007/s11055-019-00858-1,1.05,0.11,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
PCh,2019_khomenko_49,2,10.1007/s11055-019-00858-1,0.94,0.1,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
PCh,2019_khomenko_49,3,10.1007/s11055-019-00858-1,0.89,0.07,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
PCh,2019_khomenko_49,4,10.1007/s11055-019-00858-1,1.04,0.09,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
PCh,2019_khomenko_49,5,10.1007/s11055-019-00858-1,0.96,0.09,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
PCh,2019_khomenko_49,6,10.1007/s11055-019-00858-1,0.9,0.07,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
PCh,2019_monnig_54,1,10.1093/alcalc/agz062,0.353,0.045,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolites on the Descending Limb of Acute Alcohol: A Preliminary 1H MRS Study.,0.0,0.0,0.0,0.0,13.0,8.0,5.0,26.4,2.8
PCh,2019_schmitz_49,1,10.1111/apt.15256,0.0,0.0,0.42374999999999996,0.05287499999999999,0.0,0.0,Control,WM,Brain metabolic alterations in patients with long-term calcineurin inhibitor therapy after liver transplantation.,0.0,0.0,0.0,0.0,32.0,17.0,15.0,58.6,7.7
PCh,2019_wiegers_62,1,10.1007/s00125-019-4862-9,0.0,0.0,0.67125,0.06,0.67125,0.06,Control,WM,Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status.,0.265,0.042,0.713,0.047,13.0,7.0,6.0,25.5,5.5
PCh,2020_lind_40,4,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,0.51,0.07500000000000001,0.51,0.07500000000000001,Control,WM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.29254,0.0,0.66486,0.0,20.0,10.0,10.0,22.6,2.37
PCh,2020_tran_30,2,10.1111/jon.12728,0.34,0.4,0.0,0.0,0.0,0.0,Control,WM,Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis.,0.0,0.0,0.0,0.0,16.0,6.0,10.0,57.8,11.7
PCh,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,0.45375,0.0463875,0.45375,0.0463875,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
PCh,2017_suri_152,1,10.1016/j.neuroimage.2017.03.031,0.154,0.009,0.0,0.0,0.0,0.0,Control,GM,Effect of age and the APOE gene on metabolite concentrations in the posterior cingulate cortex.,0.6,0.03,0.23,0.03,30.0,13.0,17.0,23.87,4.95
PCh,2018_egerton_23,7,10.1038/s41380-018-0082-9,0.25,0.03,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
PCh,2018_egerton_23,8,10.1038/s41380-018-0082-9,0.24,0.03,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
PCh,2018_egerton_23,9,10.1038/s41380-018-0082-9,0.23,0.03,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
PCh,2018_egerton_23,1,10.1038/s41380-018-0082-9,0.26,0.04,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
PCh,2018_egerton_23,2,10.1038/s41380-018-0082-9,0.24,0.03,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
PCh,2018_egerton_23,3,10.1038/s41380-018-0082-9,0.24,0.02,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
PCh,2018_ford_10,4,10.3390/nu10121860,0.0,0.0,0.5325,0.015,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7181000000000001,0.038,0.2357,0.0458,14.0,10.0,4.0,43.0,0
PCh,2018_ford_10,2,10.3390/nu10121860,0.0,0.0,0.5175,0.015,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7239,0.0435,0.23550000000000001,0.0489,17.0,11.0,6.0,43.0,0
PCh,2018_shakory_43,1,10.1038/s41386-018-0163-0,0.0,0.0,0.89625,0.09375,0.0,0.0,Control,GM,Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.,0.6,0.11,0.35,0.091,31.0,18.0,13.0,22.2,3.1
PCh,2019_khomenko_49,7,10.1007/s11055-019-00858-1,0.98,0.1,0.0,0.0,0.0,0.0,Control,GM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
PCh,2019_khomenko_49,8,10.1007/s11055-019-00858-1,0.89,0.07,0.0,0.0,0.0,0.0,Control,GM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
PCh,2019_khomenko_49,9,10.1007/s11055-019-00858-1,0.77,0.07,0.0,0.0,0.0,0.0,Control,GM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
PCh,2019_reid_45,1,10.1093/schbul/sbx190,0.0,0.0,0.48750000000000004,0.06375,0.0,0.0,Control,GM,7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.,0.7140000000000001,0.078,0.254,0.077,21.0,5.0,16.0,23.5,4.5
PCh,2019_sheth_248,3,10.1016/j.jad.2019.01.037,0.29,0.03,0.23249999999999998,0.0,0.0,0.0,Control,GM,Reduced gamma-amino butyric acid (GABA) and glutamine in the anterior cingulate cortex (ACC) of veterans exposed to trauma.,0.703,0.03,0.297,0.037000000000000005,28.0,4.0,24.0,35.4,8.6
PCh,2020_lind_40,1,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,0.54,0.06,0.54,0.06,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.64669,0.0,0.23431000000000002,0.0,20.0,10.0,10.0,22.6,2.37
PCh,2020_lind_40,10,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,0.5775,0.08625000000000001,0.5775,0.08625000000000001,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.6731999999999999,0.0,0.3268,0.0,20.0,10.0,10.0,22.6,2.37
PCh,2020_sheth_123,2,10.1152/jn.00765.2019,0.0,0.0,0.21375,0.01125,0.0,0.0,Control,GM,Increased myoinositol in the anterior cingulate cortex of veterans with a history of traumatic brain injury: a proton magnetic resonance spectroscopy study.,0.6990000000000001,0.028999999999999998,0.3,0.028999999999999998,26.0,0.0,0.0,34.3,9.2
PCh,2020_tran_30,1,10.1111/jon.12728,0.2,0.02,0.0,0.0,0.0,0.0,Control,GM,Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis.,0.0,0.0,0.0,0.0,16.0,6.0,10.0,57.8,11.7
PCh,2021_bednarik_15,1,10.3389/fnins.2021.609485,0.0,0.0,0.675,0.037500000000000006,0.675,0.037500000000000006,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7240000000000001,0.0178,0.18600000000000003,0.031,12.0,0.0,12.0,26.0,5
PCh,2021_bednarik_15,2,10.3389/fnins.2021.609485,0.0,0.0,0.675,0.037500000000000006,0.675,0.037500000000000006,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7340000000000001,0.018000000000000002,0.17800000000000002,0.032,12.0,0.0,12.0,26.0,5
PCh,2021_steinegger_26,1,10.1111/adb.13027,0.0,0.0,1.09125,0.1275,1.09125,0.1275,Control,GM,Neurometabolic alterations in the nucleus accumbens of smokers assessed with H-1 magnetic resonance spectroscopy: The role of glutamate and neuroinflammation,0.8075,0.058899999999999994,0.1925,0.058899999999999994,25.0,0.0,20.0,26.3,4.27
GPC,2018_burger_185,17,10.1016/j.drugalcdep.2017.11.029,0.291,0.043,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
GPC,2018_burger_185,18,10.1016/j.drugalcdep.2017.11.029,0.308,0.032,0.0,0.0,0.0,0.0,Control,WM,The impact of acute and short-term methamphetamine abstinence on brain metabolites: A proton magnetic resonance spectroscopy chemical shift imaging study.,0.0,0.0,0.0,0.0,22.0,0.0,22.0,28.6,10.2
GPC,2018_egerton_23,10,10.1038/s41380-018-0082-9,0.3,0.03,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
GPC,2018_egerton_23,11,10.1038/s41380-018-0082-9,0.3,0.03,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
GPC,2018_egerton_23,12,10.1038/s41380-018-0082-9,0.31,0.02,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.08,0.06,0.92,0.06,60.0,0.0,0.0,29.0,0
GPC,2018_egerton_23,4,10.1038/s41380-018-0082-9,0.28,0.03,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
GPC,2018_egerton_23,5,10.1038/s41380-018-0082-9,0.3,0.04,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
GPC,2018_egerton_23,6,10.1038/s41380-018-0082-9,0.32,0.04,0.0,0.0,0.0,0.0,Control,WM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.1,0.06,0.9,0.06,60.0,0.0,0.0,29.0,0
GPC,2018_plitman_273,2,10.1016/j.pscychresns.2018.01.004,0.0,0.0,0.5625,0.07734375,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
GPC,2018_plitman_273,5,10.1016/j.pscychresns.2018.01.004,0.0,0.0,0.58828125,0.08671874999999998,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
GPC,2018_plitman_273,6,10.1016/j.pscychresns.2018.01.004,0.0,0.0,0.57890625,0.08906250000000002,0.0,0.0,Control,WM,Striatal neurometabolite levels in patients with schizophrenia undergoing long-term antipsychotic treatment: A proton magnetic resonance spectroscopy and reliability study.,0.28,0.04,0.64,0.05,11.0,3.0,8.0,40.73,12.95
GPC,2018_veeramuthu_25,3,10.1016/j.acra.2018.01.005,0.374,0.049,0.1546875,0.025546875,0.0,0.0,Control,WM,Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI): An In Vivo Proton Magnetic Resonance Spectroscopy (1H-MRS) Study.,0.0,0.0,0.0,0.0,13.0,5.0,8.0,27.15,4.88
GPC,2019_khomenko_49,1,10.1007/s11055-019-00858-1,1.05,0.11,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
GPC,2019_khomenko_49,2,10.1007/s11055-019-00858-1,0.94,0.1,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
GPC,2019_khomenko_49,3,10.1007/s11055-019-00858-1,0.89,0.07,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
GPC,2019_khomenko_49,4,10.1007/s11055-019-00858-1,1.04,0.09,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
GPC,2019_khomenko_49,5,10.1007/s11055-019-00858-1,0.96,0.09,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
GPC,2019_khomenko_49,6,10.1007/s11055-019-00858-1,0.9,0.07,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
GPC,2019_monnig_54,1,10.1093/alcalc/agz062,0.353,0.045,0.0,0.0,0.0,0.0,Control,WM,Cerebral Metabolites on the Descending Limb of Acute Alcohol: A Preliminary 1H MRS Study.,0.0,0.0,0.0,0.0,13.0,8.0,5.0,26.4,2.8
GPC,2019_schmitz_49,1,10.1111/apt.15256,0.0,0.0,0.26484375,0.033046874999999996,0.0,0.0,Control,WM,Brain metabolic alterations in patients with long-term calcineurin inhibitor therapy after liver transplantation.,0.0,0.0,0.0,0.0,32.0,17.0,15.0,58.6,7.7
GPC,2019_wiegers_62,1,10.1007/s00125-019-4862-9,0.0,0.0,0.41953125,0.0375,0.41953125,0.0375,Control,WM,Elevated brain glutamate levels in type 1 diabetes: correlations with glycaemic control and age of disease onset but not with hypoglycaemia awareness status.,0.265,0.042,0.713,0.047,13.0,7.0,6.0,25.5,5.5
GPC,2020_lind_40,4,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,0.31875,0.04687500000000001,0.31875,0.04687500000000001,Control,WM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.29254,0.0,0.66486,0.0,20.0,10.0,10.0,22.6,2.37
GPC,2020_tran_30,2,10.1111/jon.12728,0.34,0.4,0.0,0.0,0.0,0.0,Control,WM,Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis.,0.0,0.0,0.0,0.0,16.0,6.0,10.0,57.8,11.7
GPC,2017_marjanska_354,1,10.1016/j.neuroscience.2017.04.035,0.0,0.0,0.28359375,0.0289921875,0.28359375,0.0289921875,Control,GM,Region-specific aging of the human brain as evidenced by neurochemical profiles measured noninvasively in the posterior cingulate cortex and the occipital lobe using (1)H magnetic resonance spectroscopy at 7T.,0.61,0.041231,0.228,0.037108,17.0,10.0,7.0,21.0,1
GPC,2017_suri_152,1,10.1016/j.neuroimage.2017.03.031,0.154,0.009,0.0,0.0,0.0,0.0,Control,GM,Effect of age and the APOE gene on metabolite concentrations in the posterior cingulate cortex.,0.6,0.03,0.23,0.03,30.0,13.0,17.0,23.87,4.95
GPC,2018_egerton_23,7,10.1038/s41380-018-0082-9,0.25,0.03,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
GPC,2018_egerton_23,8,10.1038/s41380-018-0082-9,0.24,0.03,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
GPC,2018_egerton_23,9,10.1038/s41380-018-0082-9,0.23,0.03,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.65,0.03,0.12,0.03,60.0,0.0,0.0,29.0,0
GPC,2018_egerton_23,1,10.1038/s41380-018-0082-9,0.26,0.04,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
GPC,2018_egerton_23,2,10.1038/s41380-018-0082-9,0.24,0.03,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
GPC,2018_egerton_23,3,10.1038/s41380-018-0082-9,0.24,0.02,0.0,0.0,0.0,0.0,Control,GM,Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE).,0.66,0.03,0.11,0.04,60.0,0.0,0.0,29.0,0
GPC,2018_ford_10,4,10.3390/nu10121860,0.0,0.0,0.33281249999999996,0.009375,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7181000000000001,0.038,0.2357,0.0458,14.0,10.0,4.0,43.0,0
GPC,2018_ford_10,2,10.3390/nu10121860,0.0,0.0,0.3234375,0.009375,0.0,0.0,Control,GM,The Effect of a High-Dose Vitamin B Multivitamin Supplement on the Relationship between Brain Metabolism and Blood Biomarkers of Oxidative Stress: A Randomized Control Trial.,0.7239,0.0435,0.23550000000000001,0.0489,17.0,11.0,6.0,43.0,0
GPC,2018_shakory_43,1,10.1038/s41386-018-0163-0,0.0,0.0,0.56015625,0.05859375,0.0,0.0,Control,GM,Hippocampal glutamate metabolites and glial activation in clinical high risk and first episode psychosis.,0.6,0.11,0.35,0.091,31.0,18.0,13.0,22.2,3.1
GPC,2019_khomenko_49,7,10.1007/s11055-019-00858-1,0.98,0.1,0.0,0.0,0.0,0.0,Control,GM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
GPC,2019_khomenko_49,8,10.1007/s11055-019-00858-1,0.89,0.07,0.0,0.0,0.0,0.0,Control,GM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
GPC,2019_khomenko_49,9,10.1007/s11055-019-00858-1,0.77,0.07,0.0,0.0,0.0,0.0,Control,GM,Cerebral Metabolism in Patients with Cognitive Disorders: a Combined Magnetic Resonance Spectroscopy and Positron Emission Tomography Study,0.0,0.0,0.0,0.0,10.0,8.0,2.0,54.5,8.1
GPC,2019_reid_45,1,10.1093/schbul/sbx190,0.0,0.0,0.3046875,0.03984375,0.0,0.0,Control,GM,7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia.,0.7140000000000001,0.078,0.254,0.077,21.0,5.0,16.0,23.5,4.5
GPC,2019_sheth_248,3,10.1016/j.jad.2019.01.037,0.29,0.03,0.14531249999999998,0.0,0.0,0.0,Control,GM,Reduced gamma-amino butyric acid (GABA) and glutamine in the anterior cingulate cortex (ACC) of veterans exposed to trauma.,0.703,0.03,0.297,0.037000000000000005,28.0,4.0,24.0,35.4,8.6
GPC,2020_lind_40,1,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,0.3375,0.0375,0.3375,0.0375,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.64669,0.0,0.23431000000000002,0.0,20.0,10.0,10.0,22.6,2.37
GPC,2020_lind_40,10,10.1523/JNEUROSCI.2883-19.2020,0.0,0.0,0.3609375,0.05390625,0.3609375,0.05390625,Control,GM,"Regional Myo-Inositol, Creatine, and Choline Levels Are Higher at Older Age and Scale Negatively with Visuospatial Working Memory: A Cross-Sectional Proton MR Spectroscopy Study at 7 Tesla on Normal Cognitive Ageing.",0.6731999999999999,0.0,0.3268,0.0,20.0,10.0,10.0,22.6,2.37
GPC,2020_sheth_123,2,10.1152/jn.00765.2019,0.0,0.0,0.13359375,0.007031249999999999,0.0,0.0,Control,GM,Increased myoinositol in the anterior cingulate cortex of veterans with a history of traumatic brain injury: a proton magnetic resonance spectroscopy study.,0.6990000000000001,0.028999999999999998,0.3,0.028999999999999998,26.0,0.0,0.0,34.3,9.2
GPC,2020_tran_30,1,10.1111/jon.12728,0.2,0.02,0.0,0.0,0.0,0.0,Control,GM,Brain MR Spectroscopy Markers of Encephalopathy Due to Nonalcoholic Steatohepatitis.,0.0,0.0,0.0,0.0,16.0,6.0,10.0,57.8,11.7
GPC,2021_bednarik_15,1,10.3389/fnins.2021.609485,0.0,0.0,0.421875,0.023437500000000003,0.421875,0.023437500000000003,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7240000000000001,0.0178,0.18600000000000003,0.031,12.0,0.0,12.0,26.0,5
GPC,2021_bednarik_15,2,10.3389/fnins.2021.609485,0.0,0.0,0.421875,0.023437500000000003,0.421875,0.023437500000000003,Healthy,GM,Effect of Ketamine on Human Neurochemistry in Posterior Cingulate Cortex: A Pilot Magnetic Resonance Spectroscopy Study at 3 Tesla.,0.7340000000000001,0.018000000000000002,0.17800000000000002,0.032,12.0,0.0,12.0,26.0,5
GPC,2021_steinegger_26,1,10.1111/adb.13027,0.0,0.0,0.6820312500000001,0.0796875,0.6820312500000001,0.0796875,Control,GM,Neurometabolic alterations in the nucleus accumbens of smokers assessed with H-1 magnetic resonance spectroscopy: The role of glutamate and neuroinflammation,0.8075,0.058899999999999994,0.1925,0.058899999999999994,25.0,0.0,20.0,26.3,4.27
